Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:ssptacrs1614

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	JUL 28	CA/CAplus patent coverage enhanced
NEWS 3	JUL 28	EPFULL enhanced with additional legal status information from the epoline Register
NEWS 4	JUL 28	IFICDB, IFIPAT, and IFIUDB reloaded with enhancements
NEWS 5	JUL 28	STN Viewer performance improved
NEWS 6	AUG 01	INPADOCDB and INPAFAMDB coverage enhanced
NEWS 7	AUG 13	CA/CAplus enhanced with printed Chemical Abstracts page images from 1967-1998
NEWS 8	AUG 15	CAOLD to be discontinued on December 31, 2008
NEWS 9	AUG 15	CAplus currency for Korean patents enhanced
NEWS 10	AUG 27	CAS definition of basic patents expanded to ensure comprehensive access to substance and sequence information
NEWS 11	SEP 18	Support for STN Express, Versions 6.01 and earlier, to be discontinued
NEWS 12	SEP 25	CA/CAplus current-awareness alert options enhanced to accommodate supplemental CAS indexing of exemplified prophetic substances
NEWS 13	SEP 26	WPIDS, WPINDEX, and WPIX coverage of Chinese and and Korean patents enhanced
NEWS 14	SEP 29	IFICLS enhanced with new super search field
NEWS 15	SEP 29	EMBASE and EMBAL enhanced with new search and display fields
NEWS 16	SEP 30	CAS patent coverage enhanced to include exemplified prophetic substances identified in new Japanese-language patents
NEWS 17	OCT 07	EPFULL enhanced with full implementation of EPC2000
NEWS 18	OCT 07	Multiple databases enhanced for more flexible patent number searching
NEWS 19	OCT 22	Current-awareness alert (SDI) setup and editing enhanced
NEWS 20	OCT 22	WPIDS, WPINDEX, and WPIX enhanced with Canadian PCT Applications
NEWS 21	OCT 24	CHEMLIST enhanced with intermediate list of pre-registered REACH substances

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 12:29:01 ON 17 NOV 2008

=> file registry

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 12:29:17 ON 17 NOV 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 16 NOV 2008 HIGHEST RN 1072892-84-2
DICTIONARY FILE UPDATES: 16 NOV 2008 HIGHEST RN 1072892-84-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\STNEXP\Queries\10582124.str



chain nodes :
7 8 9 10 11 12 13 20 21
ring nodes :
1 2 3 4 5 6 14 15 16 17 18 19

```
chain bonds :
1-8  5-7  8-9  8-20  9-10  10-11  11-12  12-13  12-21  13-15
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6  14-15  14-19  15-16  16-17  17-18  18-19
exact/norm bonds :
5-7  8-9  9-10  10-11  12-21  13-15  14-15  14-19  15-16  16-17  17-18  18-19
exact bonds :
1-8  8-20  11-12  12-13
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6


Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:CLASS  8:CLASS  9:CLASS  10:CLASS
 11:CLASS  12:CLASS  13:CLASS  14:Atom  15:Atom  16:Atom  17:Atom  18:Atom  19:Atom
 20:CLASS  21:CLASS



L1      STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1              STR
```




```
Structure attributes must be viewed using STN Express query preparation.


=> s l1 fam ful
FULL SEARCH INITIATED 12:29:35 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -       66 TO ITERATE

100.0% PROCESSED       66 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01

L2            0 SEA FAM FUL L1

=> s l1 sss ful
FULL SEARCH INITIATED 12:29:40 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      118 TO ITERATE

100.0% PROCESSED      118 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01
```

```
L3            0 SEA SSS FUL L1

=> logoff
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   248.01     248.22

STN INTERNATIONAL LOGOFF AT 12:29:50 ON 17 NOV 2008


Connecting via Winsock to STN



Welcome to STN International!  Enter x:X

LOGINID:ssptacrs1614

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1          Web Page for STN Seminar Schedule - N. America
 NEWS  2  JUL 28  CA/CAplus patent coverage enhanced
 NEWS  3  JUL 28  EPFULL enhanced with additional legal status
                  information from the epoline Register
 NEWS  4  JUL 28  IFICDB, IFIPAT, and IFIUDB reloaded with enhancements
 NEWS  5  JUL 28  STN Viewer performance improved
 NEWS  6  AUG 01  INPADOCDB and INPAFAMDB coverage enhanced
 NEWS  7  AUG 13  CA/CAplus enhanced with printed Chemical Abstracts
                  page images from 1967-1998
 NEWS  8  AUG 15  CAOLD to be discontinued on December 31, 2008
 NEWS  9  AUG 15  CAplus currency for Korean patents enhanced
 NEWS 10  AUG 27  CAS definition of basic patents expanded to ensure
                  comprehensive access to substance and sequence
                  information
 NEWS 11  SEP 18  Support for STN Express, Versions 6.01 and earlier,
                  to be discontinued
 NEWS 12  SEP 25  CA/CAplus current-awareness alert options enhanced
                  to accommodate supplemental CAS indexing of
                  exemplified prophetic substances
 NEWS 13  SEP 26  WPIDS, WPINDEX, and WPIX coverage of Chinese and
                  and Korean patents enhanced
 NEWS 14  SEP 29  IFICLS enhanced with new super search field
 NEWS 15  SEP 29  EMBASE and EMBAL enhanced with new search and
                  display fields
 NEWS 16  SEP 30  CAS patent coverage enhanced to include exemplified
                  prophetic substances identified in new Japanese-
                  language patents
 NEWS 17  OCT 07  EPFULL enhanced with full implementation of EPC2000
 NEWS 18  OCT 07  Multiple databases enhanced for more flexible patent
                  number searching
 NEWS 19  OCT 22  Current-awareness alert (SDI) setup and editing
                  enhanced
 NEWS 20  OCT 22  WPIDS, WPINDEX, and WPIX enhanced with Canadian PCT
                  Applications
```

```
 NEWS 21  OCT 24  CHEMLIST enhanced with intermediate list of
                  pre-registered REACH substances

 NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
              AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 13:03:06 ON 17 NOV 2008

=> file registry
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.21       0.21

FILE 'REGISTRY' ENTERED AT 13:03:15 ON 17 NOV 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   16 NOV 2008  HIGHEST RN 1072892-84-2
DICTIONARY FILE UPDATES:  16 NOV 2008  HIGHEST RN 1072892-84-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\STNEXP\Queries\10582124a.str
```



chain nodes :
7 8 9 10 11 12 19 20
ring nodes :
1 2 3 4 5 6 13 14 15 16 17 18
chain bonds :
1-7 7-8 7-19 8-9 9-10 10-11 11-12 11-20 12-14
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 13-14 13-18 14-15 15-16 16-17 17-18
exact/norm bonds :
7-8 8-9 9-10 11-20 12-14 13-14 13-18 14-15 15-16 16-17 17-18
exact bonds :
1-7 7-19 10-11 11-12
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:CLASS 12:CLASS 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:CLASS
20:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss ful
FULL SEARCH INITIATED 13:03:31 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 118 TO ITERATE

100.0% PROCESSED 118 ITERATIONS 31 ANSWERS
SEARCH TIME: 00.00.01

L2 31 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 178.36 178.57

FILE 'CAPLUS' ENTERED AT 13:03:35 ON 17 NOV 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 17 Nov 2008 VOL 149 ISS 21
FILE LAST UPDATED: 16 Nov 2008 (20081116/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/legal/infopolicy.html

=> s l2
L3 75 L2

=> s l3 and (amyotroph? or als)
7910 AMYOTROPH?
6582 ALS
L4 8 L3 AND (AMYOTROPH? OR ALS)

=> d l4 ibib abs 1-8

L4 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2008:918262 CAPLUS
DOCUMENT NUMBER: 149:258394
TITLE: Arimoclomol at dosages up to 300 Mg/day is well tolerated and safe in amyotrophic lateral sclerosis
AUTHOR(S): Cudkowicz, Merit E.; Shefner, Jeremy M.; Simpson,

Elizabeth; Grasso, Daniela; Yu, Hong; Zhang, Hui; Shui, Amy; Schoenfeld, David; Brown, Robert H.; Wieland, Scott; Barber, Jack R.

CORPORATE SOURCE: NORTHEAST ALS CONSORTIUM, Neurology Clinical Trials Unit, Massachussets General Hospital, Charlestown, MA, 02129, USA

SOURCE: Muscle & Nerve (2008), 38(1), 837-844
CODEN: MUNEDE; ISSN: 0148-639X
PUBLISHER: John Wiley & Sons, Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Arimoclomol is an investigational drug for amyotrophic lateral sclerosis (ALS) that amplifies heat shock protein gene expression during cell stress. The objectives of the present study were to assess the safety, tolerability, and pharmacokinetics of arimoclomol in ALS. Eighty-four participants with ALS received arimoclomol at one of three oral doses (25, 50, or 100 mg three times daily) or placebo. The primary outcome measure was safety and tolerability. A subset of 44 participants provided serum and cerebrospinal fluid (CSF) samples for pharmacokinetic anal. Participants who completed 12 wk of treatment could enroll in a 6-mo open-label study. Arimoclomol at doses up to 300 mg/day was well tolerated and safe. Arimoclomol resulted in dose-linear pharmacol. exposures and the half-life did not change with continued treatment. Arimoclomol CSF levels increased with dose. Arimoclomol was shown to be safe, and it crosses the blood-brain barrier. Serum pharmacokinetic profiles support dosing of three times per day. An efficacy study in ALS is planned.

REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2008:411857 CAPLUS
DOCUMENT NUMBER: 148:410753

TITLE: Composition comprising hydroxyamine compound for treating diseases associated with neurodegeneration

INVENTOR(S): Barber, Jack R.
PATENT ASSIGNEE(S): Cytrx Corporation, USA

SOURCE: PCT Int. Appl., 119pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008039514	A1	20080403	WO 2007-US20853	20070926
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 20080227813	A1	20080918	US 2007-904534	20070926

PRIORITY APPLN. INFO.: US 2006-847606P P 20060926
US 2006-852791P P 20061018

OTHER SOURCE(S): MARPAT 148:410753

AB The present invention relates to methods for treating diseases, conditions or disorders using hydroxyamine compds., and in particular, N-[2-hydroxy-3- (1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride, alone or in combination with one or more other therapeutic agents, for the treatment of conditions, disorders or diseases associated with neurodegeneration in the central nervous system. The present invention also relates to pharmaceutical compns. comprising hydroxyamine compds., an addnl. therapeutic agent and a pharmaceutically acceptable carrier and methods for treating diseases using them. Thus, capsule was prepared containing N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride 25 mg, MC cellulose 252 mg, and talc 3 mg.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2008:223578 CAPLUS

DOCUMENT NUMBER: 148:269430

TITLE: Methods and compositions for the treatment of neurodegenerative disorders such as Huntington's disease

INVENTOR(S): Jin, Xiaowei; Wilson, Amy Beth; Staunton, Jane; MacDonald, Douglas

PATENT ASSIGNEE(S): Combinatorx, Incorporated, USA; Chdi, Inc.

SOURCE: PCT Int. Appl., 127pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2008021210	A2	20080221	WO 2007-US17751		20070810
WO 2008021210	A3	20081030			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
US 20080044390	A1	20080221	US 2007-891552		20070810
PRIORITY APPLN. INFO.:			US 2006-837448P	P	20060811
			US 2007-898479P	P	20070131
			US 2007-925777P	P	20070423
			US 2007-958832P	P	20070709

AB The present invention features compns., kits, and methods for treating, preventing, and ameliorating neurodegenerative disorders, e.g., Huntington's disease (HD). Screening methods for identifying candidate compds. that treat, prevent, or ameliorate neurodegenerative disorders, e.g., HD, are provided. Thus, N-terminal fragment of Htt has been shown to form protein aggregates in the nucleus, cytoplasm and processes of neurons in human HD patients and in HD animal models, as well as in many cellular models. Because of their similarities to neurons, rat pheochromocytoma PC12 cells have provided a useful model for studying neuronal cell biol.; in addition, PC12 cells are readily transfected,

selected and cloned. In order to perform screening according to a method of the present invention, PC12 cells were obtained that stably incorporated a plasmid that inducibly expresses a toxic expanded polyglutamine (103 glutamine) form of exon 1 of Htt, fused to the marker EGFP. Using the engineered PC12/HttN90Q103 cell line, a high throughput assay to screen small mols. for their ability to prevent mutant Htt exon 1-induced cell death was developed and optimized.

L4 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:1424894 CAPLUS
DOCUMENT NUMBER: 148:492092
TITLE: Heat shock proteins and protection of the nervous system
AUTHOR(S): Brown, Ian R.
CORPORATE SOURCE: Center for the Neurobiology of Stress, University of Toronto at Scarborough, Toronto, ON, Can.
SOURCE: Annals of the New York Academy of Sciences (2007), 1113(Stress Responses in Biology and Medicine), 147-158
CODEN: ANYAA9; ISSN: 0077-8923
PUBLISHER: Blackwell Publishing, Inc.
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
AB A review. Manipulation of the cellular stress response offers strategies to protect brain cells from damage induced by ischemia and neurodegenerative diseases. Overexpression of Hsp70 reduced ischemic injury in the mammalian brain. Investigation of the domains within Hsp70 that confers ischemic neuroprotection revealed the importance of the carboxyl-terminal domain. Arimoclomol, a coinducer of heat shock proteins, delayed progression of amyotrophic lateral sclerosis (ALS) in a mouse model in which motor neurons in the spinal cord and motor cortex degenerate. Celastrol, a promising candidate as an agent to counter neurodegenerative diseases, induced expression of a set of Hsps in differentiated neurons grown in tissue culture. Heat shock "preconditioning" protected the nervous system at the functional level of the synapse and selective overexpression of Hsp70 enhanced the level of synaptic protection. Following hyperthermia, constitutively expressed Hsc70 increased in synapse-rich areas of the brain where it assocs. with Hsp40 to form a complex that can refold denatured proteins. Stress tolerance in neurons is not solely dependent on their own Hsps but can be supplemented by Hsps from adjacent glial cells. Hence, application of exogenous Hsps at neural injury sites is an effective strategy to maintain neuronal viability.
REFERENCE COUNT: 72 THERE ARE 72 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:576156 CAPLUS
DOCUMENT NUMBER: 146:514797
TITLE: Use of (2-hydroxy-3-(1-piperidinyl)-propoxy)-pyridine carboximidoyl chloride for treatment of selected neurological diseases
INVENTOR(S): Karpati, Gyoergy; Molnar, Maria Judit
PATENT ASSIGNEE(S): Hung.
SOURCE: Hung. Pat. Appl., 9pp.
CODEN: HUXXCV
DOCUMENT TYPE: Patent
LANGUAGE: Hungarian
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

HU 9904451	A2	20021128	HU 1999-4451	19991201
PRIORITY APPLN. INFO.:			HU 1999-4451	19991201

AB The subject of the invention is the new therapeutic application of [2-hydroxy-3-(1-piperidinyl)-propoxy] pyridine-carboxyimidoyl chloride -maleate to treat sporadic amyotrophic lateral sclerosis, Friedreich disease, mitochondrial diseases accompanied by the damage of oxidative phosphorylation (OXPHOS) and in the case of inclusion testes myositis, in the presymptomatic and symptomatic phase, to prevent the harmful effects of primary etiol. factors and to alleviate the progression and clin. symptoms of the disease. According to the invention, the pharmaceutically acceptable derivative of the [2-hydroxy-3-(1-piperidinyl)propoxy]-pyridine carboxy imidoyl-chloride-maleate is used together with a pharmaceutically acceptable adjuvant, diluter or carrier in the neurol. clin. pictures defined above.

L4 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:598700 CAPLUS
DOCUMENT NUMBER: 145:499471
TITLE: Neuroprotective agents for clinical trials in ALS
AUTHOR(S): Traynor, B. J.; Bruijn, L.; Conwit, R.; Beal, F.; O'Neill, G.; Fagan, S. C.; Cudkowicz, M. E.
CORPORATE SOURCE: Neurology Clinical Trials Unit, Department of Neurology, Massachusetts General Hospital, Boston, MA, USA
SOURCE: Neurology (2006), 67(1), 20-27
CODEN: NEURAI; ISSN: 0028-3878
PUBLISHER: Lippincott Williams & Wilkins
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English

AB A review. Background: Riluzole is currently the only Food and Drug Administration-approved treatment for ALS, but its effect on survival is modest. Objective: To identify potential neuroprotective agents for testing in phase III clin. trials and to outline which data need to be collected for each drug. Methods: The authors identified 113 compds. by inviting input from academic clinicians and researchers and via literature review to identify agents that have been tested in ALS animal models and in patients with ALS. The list was initially narrowed to 24 agents based on an evaluation of scientific rationale, toxicity, and efficacy in previous animal and human studies. These 24 drugs underwent more detailed pharmacol. evaluation. Results: Twenty drugs were selected as suitable for further development as treatments for patients with ALS. Talampanel and tamoxifen have completed early phase II trials and have demonstrated preliminary efficacy. Other agents (ceftriaxone, minocycline, ONO-2506, and IGF-1 polypeptide) are already in phase III trials involving large nos. of patients with ALS. Remaining agents (AEOL 10150, arimoclomol, celastrol, coenzyme Q10, copaxone, IGF-1-viral delivery, memantine, NAALADase inhibitors, nimesulide, scriptaid, sodium phenylbutyrate, thalidomide, trehalose) require addnl. preclin. animal data, human toxicity and pharmacokinetic data including CNS penetration prior to proceeding to large scale phase III human testing. Further development of riluzole analogs should be considered. Conclusions: Several potential neuroprotective compds., representing a wide range of mechanisms, are available and merit further investigation in ALS.

REFERENCE COUNT: 86 THERE ARE 86 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:409316 CAPLUS
DOCUMENT NUMBER: 142:441894

TITLE: Use of a hydroximic acid halide derivative in the treatment of neurodegenerative diseases
INVENTOR(S): Greensmith, Linda; Burnstock, Geoffrey; Urbanics, Rudolf
PATENT ASSIGNEE(S): Biorex Kutato es Fejlesztoe Rt., Hung.
SOURCE: PCT Int. Appl., 24 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005041965	A1	20050512	WO 2004-HU98	20041025
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004285343	A1	20050512	AU 2004-285343	20041025
CA 2544332	A1	20050512	CA 2004-2544332	20041025
EP 1696922	A1	20060906	EP 2004-791657	20041025
EP 1696922	B1	20080924		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
BR 2004015625	A	20061212	BR 2004-15625	20041025
CN 1901913	A	20070124	CN 2004-80039619	20041025
JP 2007509920	T	20070419	JP 2006-537449	20041025
AT 409038	T	20081015	AT 2004-791657	20041025
MX 2006PA04814	A	20061211	MX 2006-PA4814	20060428
NO 2006002401	A	20060727	NO 2006-2401	20060526
IN 2006KN01464	A	20070504	IN 2006-KN1464	20060530
US 20080039497	A1	20080214	US 2007-582124	20070510
PRIORITY APPLN. INFO.:			HU 2003-3584 A	20031030
			WO 2004-HU98 W	20041025

AB The invention relates to the use of a chemical substance selected from the group consisting of N-[2-hydroxy-3-(1-piperidinyl)-propoxyl]-pyridine-1-oxide-3-carboximidoyl chloride, the optically active enantiomers and the mixts. of enantiomers thereof and pharmaceutically acceptable salts of the racemic and optically active compds. in the preparation of a pharmaceutical composition for the treatment or prevention of neurodegenerative diseases.
REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:263763 CAPLUS
DOCUMENT NUMBER: 140:399884
TITLE: Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice
AUTHOR(S): Kieran, Dairin; Kalmar, Bernadett; Dick, James R. T.; Riddoch-Contreras, Joanna; Burnstock, Geoffrey; Greensmith, Linda
CORPORATE SOURCE: The National Hospital for Neurology and Neurosurgery, Institute of Neurology, Sobell Department of Motor

Neuroscience and Movement Disorders, The Graham Watts Laboratory, University College London, London, WC1N 3BG, UK
SOURCE: Nature Medicine (New York, NY, United States) (2004), 10(4), 402-405
CODEN: NAMEFI; ISSN: 1078-8956
PUBLISHER: Nature Publishing Group
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative condition in which motoneurons of the spinal cord and motor cortex die, resulting in progressive paralysis. This condition has no cure and results in eventual death, usually within 1-5 yr of diagnosis. Although the specific etiol. of ALS is unknown, 20% of familial cases of the disease carry mutations in the gene encoding Cu/Zn superoxide dismutase-1 (SOD1). Transgenic mice overexpressing human mutant SOD1 have a phenotype and pathol. that are very similar to that seen in human ALS patients. Here we show that treatment with arimoclomol, a coinducer of heat shock proteins (HSPs), significantly delays disease progression in mice expressing a SOD1 mutant in which glycine is substituted with alanine at position 93 (SOD1G93A). Arimoclomol-treated SOD1G93A mice show marked improvement in hind limb muscle function and motoneuron survival in the later stages of the disease, resulting in a 22% increase in lifespan. Pharmacol. activation of the heat shock response may therefore be a successful therapeutic approach to treating ALS, and possibly other neurodegenerative diseases.
REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file registry

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	36.64	215.21

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-6.40	-6.40

FILE 'REGISTRY' ENTERED AT 13:15:05 ON 17 NOV 2008

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 16 NOV 2008 HIGHEST RN 1072892-84-2
DICTIONARY FILE UPDATES: 16 NOV 2008 HIGHEST RN 1072892-84-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

```
=> e arimoclomol
E1            1     ARIMIDS/BI
E2            1     ARIMOCLOM/BI
E3            1 --> ARIMOCLOMOL/BI
E4            2     ARIMOL/BI
E5            2     ARIMOSA/BI
E6            1     ARIMOTO/BI
E7          130     ARIN/BI
E8           17     ARINA/BI
E9            1     ARINAE/BI
E10           1     ARINAMINE/BI
E11           4     ARINATE/BI
E12          56     ARINE/BI

=> s e3
L5            1 ARIMOCLOMOL/BI

=> d l5

L5   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2008 ACS on STN
RN   289893-25-0  REGISTRY
ED   Entered STN:  21 Sep 2000
CN   3-Pyridinecarboximidoyl chloride, N-[(2R)-2-hydroxy-3-(1-
     piperidinyl)propoxy]-, 1-oxide  (CA INDEX NAME)
OTHER NAMES:
CN   Arimoclomol
FS   STEREOSEARCH
MF   C14 H20 Cl N3 O3
CI   COM
SR   CA
LC   STN Files:   ADISINSIGHT, CA, CAPLUS, CBNB, EMBASE, IMSRESEARCH, PROUSDDR,
       SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL

Absolute stereochemistry.
Double bond geometry unknown.
```




```
**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

              10 REFERENCES IN FILE CA (1907 TO DATE)
               1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
              10 REFERENCES IN FILE CAPLUS (1907 TO DATE)


=> e brx
E1            6     BRWR1/BI
E2            1     BRWY/BI
E3           32 --> BRX/BI
E4            6     BRX1/BI
E5            2     BRX1A/BI
E6            2     BRX1B/BI
```

```
E7            6     BRXE/BI
E8            2     BRXE10/BI
E9            2     BRXE11/BI
E10           2     BRXE12/BI
E11           2     BRXE13/BI
E12           2     BRXE14/BI

=> e brx220
E1            2     BRX1A/BI
E2            2     BRX1B/BI
E3            0 --> BRX220/BI
E4            6     BRXE/BI
E5            2     BRXE10/BI
E6            2     BRXE11/BI
E7            2     BRXE12/BI
E8            2     BRXE13/BI
E9            2     BRXE14/BI
E10           2     BRXE15/BI
E11           2     BRXE16/BI
E12           3     BRXE2/BI

=> s e3
L6            0 BRX220/BI

=> e brx
E1            6     BRWR1/BI
E2            1     BRWY/BI
E3           32 --> BRX/BI
E4            6     BRX1/BI
E5            2     BRX1A/BI
E6            2     BRX1B/BI
E7            6     BRXE/BI
E8            2     BRXE10/BI
E9            2     BRXE11/BI
E10           2     BRXE12/BI
E11           2     BRXE13/BI
E12           2     BRXE14/BI

=> s e3
L7           32 BRX/BI

=> d l7 1-32

L7   ANSWER 1 OF 32  REGISTRY  COPYRIGHT 2008 ACS on STN
RN   909311-85-9  REGISTRY
ED   Entered STN:  02 Oct 2006
CN   Glucagon-like peptide 1 [2-glycine,28-alanine,31-glycine] (human clone
     WO2006/096515-SEQID-12) fusion protein with peptide (synthetic) fusion
     protein with transferrin (human) (9CI)  (CA INDEX NAME)
OTHER NAMES:
CN   20: PN: WO2006096515 SEQID: 12 claimed protein
CN   BRX 0585
CN   GLP 1Tf
FS   PROTEIN SEQUENCE
MF   Unspecified
CI   MAN
SR   CA
LC   STN Files:   CA, CAPLUS, TOXCENTER, USPATFULL

**RELATED SEQUENCES AVAILABLE WITH SEQLINK**

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
```

*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7 ANSWER 2 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN
RN 889930-43-2 REGISTRY
ED Entered STN: 28 Jun 2006
CN Protein (Arabidopsis thaliana strain ecotype-Uk-2 gene BRX (BREVIS RADIX)) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN GenBank ABG25053
CN GenBank ABG25053 (Translated from: GenBank AY702649)
FS PROTEIN SEQUENCE
MF Unspecified
CI MAN
SR GenBank
LC STN Files: CA, CAPLUS

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7 ANSWER 3 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN
RN 889930-42-1 REGISTRY
ED Entered STN: 28 Jun 2006
CN DNA (Arabidopsis thaliana strain ecotype-Uk-2 gene BRX (BREVIS RADIX) protein cDNA) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN GenBank AY702649
FS NUCLEIC ACID SEQUENCE
MF Unspecified
CI MAN
SR GenBank
LC STN Files: CA, CAPLUS, GENBANK

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7 ANSWER 4 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN
RN 889930-41-0 REGISTRY
ED Entered STN: 28 Jun 2006
CN Protein (Arabidopsis thaliana strain ecotype-Uk-1 gene BRX (BREVIS RADIX) truncated isoform) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN GenBank ABG25052
CN GenBank ABG25052 (Translated from: GenBank AY702648)
FS PROTEIN SEQUENCE
MF Unspecified
CI MAN
SR GenBank
LC STN Files: CA, CAPLUS

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7 ANSWER 5 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN
RN 889930-40-9 REGISTRY

ED Entered STN: 28 Jun 2006
CN DNA (Arabidopsis thaliana strain ecotype-Uk-1 gene BRX (BREVIS RADIX)
    protein truncated isoform cDNA plus 3'-flank) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN GenBank AY702648
FS NUCLEIC ACID SEQUENCE
MF Unspecified
CI MAN
SR GenBank
LC STN Files: CA, CAPLUS, GENBANK

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
              1 REFERENCES IN FILE CA (1907 TO DATE)
              1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7 ANSWER 6 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN
RN 850069-82-8 REGISTRY
ED Entered STN: 09 May 2005
CN Propanedioic acid, (6aS,11bR)-3-(acetyloxy)-7,11b-dihydrobenz[b]indeno[1,2-
    d]pyran-6a,9,10(6H)-triyl trimethyl ester (9CI) (CA INDEX NAME)
OTHER NAMES:
CN BRX 018
FS STEREOSEARCH
MF C30 H28 O15
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

              1 REFERENCES IN FILE CA (1907 TO DATE)
              1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7 ANSWER 7 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN
RN 688066-21-9 REGISTRY
ED Entered STN: 01 Jun 2004
CN Protein (Arabidopsis thaliana gene BRX) (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE
MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7 ANSWER 8 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN
RN 502923-63-9 REGISTRY
ED Entered STN: 14 Apr 2003
CN Amplex BRX (9CI) (CA INDEX NAME)
ENTE An activator for pectinase mixture biopolishing agent (Color Center S.A., Spain)
MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7 ANSWER 9 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN
RN 496816-64-9 REGISTRY
ED Entered STN: 03 Mar 2003
CN 3-Pyridinecarboximidoyl chloride, N-[(2R)-2-hydroxy-3-(1-piperidinyl)propoxy]-, [C(Z)]-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN BRX 51
FS STEREOSEARCH
MF C14 H20 Cl N3 O2 . C4 H4 O4
SR CA
LC STN Files: CA, CAPLUS

CM 1

CRN 496816-63-8
CMF C14 H20 Cl N3 O2

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7 ANSWER 10 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN
RN 496816-62-7 REGISTRY
ED Entered STN: 03 Mar 2003
CN 3-Pyridinecarboximidoyl chloride, N-[(2S)-2-hydroxy-3-(1-piperidinyl)propoxy]-, [C(Z)]-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN BRX 53
FS STEREOSEARCH
MF C14 H20 Cl N3 O2 . C4 H4 O4
SR CA
LC STN Files: CA, CAPLUS

CM 1

CRN 496816-61-6
CMF C14 H20 Cl N3 O2

Absolute stereochemistry. Rotation (-).
Double bond geometry as shown.



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7 ANSWER 11 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN
RN 412507-73-4 REGISTRY
ED Entered STN: 08 May 2002
CN DNA (mouse strain C57BL/6J clone UI-M-BH3-brx-a-05-0-UI EST (expressed sequence tag)) (CA INDEX NAME)
OTHER NAMES:
CN GenBank BM933144
FS NUCLEIC ACID SEQUENCE
MF Unspecified
CI MAN
SR GenBank
LC STN Files: CA, CAPLUS, GENBANK, TOXCENTER

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7 ANSWER 12 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN
RN 392081-00-4 REGISTRY
ED Entered STN: 13 Feb 2002
CN DNA (human clone pDR2 gene BRX cDNA) (CA INDEX NAME)
OTHER NAMES:
CN 469: PN: WO2007132883 PAGE: 41 unclaimed DNA
CN GenBank AF126008
FS NUCLEIC ACID SEQUENCE
MF Unspecified
CI MAN
SR GenBank
LC STN Files: CA, CAPLUS, GENBANK, TOXCENTER

RELATED SEQUENCES AVAILABLE WITH SEQLINK

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7 ANSWER 13 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN
RN 388566-72-1 REGISTRY
ED Entered STN: 31 Jan 2002
CN BRX-Q (9CI) (CA INDEX NAME)
ENTE An exerimental acrylamido-based ion-exchanger for protein chromatography
(Bio-Rad Laboratories, Hercules, CA)
MF Unspecified
CI PMS, MAN
PCT Manual registration
SR CA
LC STN Files: CA, CAPLUS

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7 ANSWER 14 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN
RN 344670-25-3 REGISTRY
ED Entered STN: 05 Jul 2001
CN DNA (mouse strain C57BL/6J clone UI-M-BH3-brx-b-05-0-UI EST
(expressed sequence tag)) (CA INDEX NAME)
OTHER NAMES:
CN GenBank BI133445
FS NUCLEIC ACID SEQUENCE
MF Unspecified
CI MAN
SR GenBank
LC STN Files: CA, CAPLUS, GENBANK, TOXCENTER

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7 ANSWER 15 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN
RN 326984-24-1 REGISTRY

ED   Entered STN: 13 Mar 2001
CN   DNA (Rattus norvegicus strain Sprague-Dawley clone
     UI-R-CV1-brx-h-03-0-UI EST (expressed sequence tag)) (9CI) (CA INDEX
     NAME)
OTHER NAMES:
CN   410: PN: US20050084872 TABLE: 9 claimed DNA
CN   GenBank BG373361
FS   NUCLEIC ACID SEQUENCE
MF   Unspecified
CI   MAN
SR   GenBank
LC   STN Files: CA, CAPLUS, GENBANK, TOXCENTER, USPATFULL

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
               1 REFERENCES IN FILE CA (1907 TO DATE)
               1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7   ANSWER 16 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN
RN   308063-34-5 REGISTRY *
* Use of this CAS Registry Number alone as a search term in other STN files may
  result in incomplete search results. For additional information, enter HELP
  RN* at an online arrow prompt (=>).
ED   Entered STN: 12 Dec 2000
CN   Rubber, butadiene, of cis-1,4-configuration (CA INDEX NAME)
OTHER NAMES:
CN   Afdene Buna CB 11
CN   Ameripol CB
CN   Ameripol CB 200
CN   Ameripol CB 220
CN   Ameripol CB 221
CN   B 27
CN   B 27 (rubber)
CN   B 37
CN   B 37 (rubber)
CN   BCP 820
CN   BR 01
CN   BR 10
CN   BR 11
CN   BR 1208
CN   BR 1220
CN   BR 1220N
CN   BR 1220SG
CN   BR 1241
CN   BR 1280
CN   BR 130B
CN   BR 133P
CN   BR 150
CN   BR 150B
CN   BR 150L
CN   BR 153A
CN   BR 18
CN   BR 230
CN   BR 31
CN   BR 360L
CN   BR 40
CN   BR 51
CN   BR 60
CN   BR 700
CN   BR 700 (rubber)
CN   BR 701
CN   BR 730

CN BR 9000
CN BR 9002
CN BR 9002L
CN BR 9004
CN BR 9053
CN BRX 5000
CN Bud 1207
CN Bud 1254
CN Budene 1207
CN Budene 1208
CN Budene 1254
CN Budene 1280
CN Budene 207
CN Buna CB 10
CN Nipol BRX 5000
ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT - Use FCN, FIDE, or ALL for DISPLAY
MF Unspecified
CI MAN, CTS
SR CA

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L7 ANSWER 17 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN
RN 289893-26-1 REGISTRY
ED Entered STN: 21 Sep 2000
CN 3-Pyridinecarboximidoyl chloride, N-[(2R)-2-hydroxy-3-(1-piperidinyl)propoxy]-, 1-oxide, (2Z)-2-butenedioate (1:1) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 3-Pyridinecarboximidoyl chloride, N-[(2R)-2-hydroxy-3-(1-piperidinyl)propoxy]-, 1-oxide, (2Z)-2-butenedioate (1:1) (salt) (9CI)
OTHER NAMES:
CN BRX 220
FS STEREOSEARCH
MF C14 H20 Cl N3 O3 . C4 H4 O4
SR CA
LC STN Files: BIOSIS, CA, CAPLUS, IMSDRUGNEWS, IMSRESEARCH, PROUSDDR, SYNTHLINE, TOXCENTER, USPAT2, USPATFULL

CM 1

CRN 289893-25-0
CMF C14 H20 Cl N3 O3

Absolute stereochemistry.
Double bond geometry unknown.



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



8 REFERENCES IN FILE CA (1907 TO DATE)
8 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7 ANSWER 18 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN
RN 222187-17-9 REGISTRY
ED Entered STN: 07 May 1999
CN DNA (human clone 11.1/2.2 gene brx protein cDNA plus flanks) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN DNA (human clone 11.1/2.2 gene brx nuclear receptor-binding auxiliary protein Brx cDNA plus flanks)
CN DNA (human clone 11.1/2.2 gene brx putative rho guanine nucleotide exchange factor cDNA plus flanks)
FS NUCLEIC ACID SEQUENCE
MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7 ANSWER 19 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN
RN 222187-15-7 REGISTRY
ED Entered STN: 07 May 1999
CN Protein (human clone 11.1/2.2 gene brx reduced) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN Nuclear receptor-binding auxiliary protein Brx (human clone 11.1/2.2 gene brx reduced)
CN Putative Rho guanine nucleotide exchange factor (human clone 11.1/2.2 gene brx reduced)
FS PROTEIN SEQUENCE
MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

RELATED SEQUENCES AVAILABLE WITH SEQLINK

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7 ANSWER 20 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN
RN 215233-82-2 REGISTRY
ED Entered STN: 08 Dec 1998
CN Benzenecarboximidamide, N-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-N'-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)
OTHER NAMES:
CN BRX 156

MF C20 H27 N3 O2 . Cl H
SR CA
LC STN Files: BIOSIS, CA, CAPLUS, TOXCENTER, USPATFULL
CRN (774166-55-1)



3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7 ANSWER 21 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN
RN 210170-31-3 REGISTRY
ED Entered STN: 20 Aug 1998
CN Protein Brx (human) (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE
MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7 ANSWER 22 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN
RN 203805-20-3 REGISTRY
ED Entered STN: 08 Apr 1998
CN 2H-1,2,4-Oxadiazine, 5,6-dihydro-5-(1-piperidinylmethyl)-3-(3-pyridinyl)-
(CA INDEX NAME)
OTHER NAMES:
CN BRX 005
CN BRX 235
DR 191159-87-2
MF C14 H20 N4 O
SR CA
LC STN Files: BIOSIS, CA, CAPLUS, CHEMCATS, PROUSDDR, SYNTHLINE, TOXCENTER,
USPAT2, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

```
               5 REFERENCES IN FILE CA (1907 TO DATE)
               5 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7   ANSWER 23 OF 32  REGISTRY  COPYRIGHT 2008 ACS on STN
RN   201556-27-6  REGISTRY
ED   Entered STN:  19 Feb 1998
CN   BRX 5 (primer) (9CI)  (CA INDEX NAME)
OTHER NAMES:
CN   BRX 5
ENTE A polyimide primer (Cytec)
MF   Unspecified
CI   PMS, MAN
PCT  Manual registration
SR   CA
LC   STN Files:   BIOSIS, CA, CAPLUS, TOXCENTER, USPATFULL

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
               4 REFERENCES IN FILE CA (1907 TO DATE)
               4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7   ANSWER 24 OF 32  REGISTRY  COPYRIGHT 2008 ACS on STN
RN   181858-04-8  REGISTRY
ED   Entered STN:  10 Oct 1996
CN   RNA (measles virus strain Brx hemagglutinin gene
     fragment-complementary) (9CI)  (CA INDEX NAME)
OTHER NAMES:
CN   GenBank Z80797
FS   NUCLEIC ACID SEQUENCE
MF   Unspecified
CI   MAN
SR   GenBank
LC   STN Files:   CA, CAPLUS, GENBANK

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
               1 REFERENCES IN FILE CA (1907 TO DATE)
               1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7   ANSWER 25 OF 32  REGISTRY  COPYRIGHT 2008 ACS on STN
RN   164479-36-1  REGISTRY
ED   Entered STN:  07 Jul 1995
CN   RNA (measles virus strain Brx nucleocapsid protein gene fragment)
     (9CI)  (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN   Ribonucleic acid (measles virus strain Brx nucleocapsid protein gene
     fragment)
OTHER NAMES:
CN   GenBank X84879
FS   NUCLEIC ACID SEQUENCE
MF   Unspecified
CI   MAN
SR   GenBank
LC   STN Files:   CA, CAPLUS, GENBANK

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
               1 REFERENCES IN FILE CA (1907 TO DATE)
               1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7   ANSWER 26 OF 32  REGISTRY  COPYRIGHT 2008 ACS on STN
RN   63394-00-3  REGISTRY *
* Use of this CAS Registry Number alone as a search term in other STN files may
```

result in incomplete search results. For additional information, enter HELP RN* at an online arrow prompt (=>).

ED Entered STN: 16 Nov 1984
CN Rubber, butadiene (CA INDEX NAME)
OTHER NAMES:
CN 150L
CN 150L (rubber)
CN 60P
CN A 24
CN Alkadienes, rubber
CN Ameripol CB 441
CN Ameripol CB 880
CN Asadene
CN Asadene 35AS
CN Asadene 35NF
CN Asadene 55AS
CN Asadene 55NF
CN Asadene AS
CN Asadene NF 35A
CN Asadene NF 35AS
CN Asadene NF 50R
CN Asaprene 610AX
CN Asaprene 700A
CN Asaprene 720A
CN Asaprene 720AX
CN Asaprene 730AX
CN Asaprene 755A
CN Asaprene 756A
CN Asaprene 760A
CN Asaprene BR 730A
CN Austrapol 1220
CN Bayer 550
CN Bon RI 1
CN BR 02L
CN BR 02LL
CN BR 1200
CN BR 1202G
CN BR 1203
CN BR 1207
CN BR 1220L
CN BR 1220SU
CN BR 1250
CN BR 1441
CN BR 15HB
CN BR 200
CN BR 200 (rubber)
CN BR 23SH
CN BR 3505
CN BR 401
CN BR 401 (rubber)
CN BR 55F
CN BR 90
CN BR 900
CN BR 9001
CN BR 9073
CN BRX 3000
ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT - Use FCN, FIDE, or ALL for DISPLAY
DR 62361-95-9, 51426-11-0, 178234-67-8
MF Unspecified
CI PMS, MAN, CTS
PCT Manual registration

LC STN Files: ADISNEWS, AGRICOLA, BIOSIS, CA, CAPLUS, CHEMCATS, CHEMLIST, CIN, CSCHEM, TOXCENTER

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L7 ANSWER 27 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN
RN 3701-40-4 REGISTRY
ED Entered STN: 16 Nov 1984
CN 2,7-Naphthalenedisulfonic acid, 4-hydroxy-3-[2-[4'-[2-(2-hydroxy-1-naphthalenyl)diazenyl]-2,2'-dimethyl[1,1'-biphenyl]-4-yl]diazenyl]-, sodium salt (1:2) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 2,7-Naphthalenedisulfonic acid, 4-hydroxy-3-[[4'-[(2-hydroxy-1-naphthalenyl)azo]-2,2'-dimethyl[1,1'-biphenyl]-4-yl]azo]-, disodium salt (9CI)
CN C.I. Acid Red 99 (7CI)
CN C.I. Acid Red 99, disodium salt (8CI)
OTHER NAMES:
CN Acid Leather Red 2BG
CN Acid Red 99
CN Acidine Red RD
CN Airedale Red RM
CN Benzyl Fast Red 2BG
CN Best Acid Milling Red FRS
CN Brilliant Milling Red
CN C.I. 23285
CN Calcocid Milling Red RC
CN Coomassie Red R
CN Dynacid Red RS
CN Elite Fast Red BG
CN Elite Fast Red R
CN Elite Fast Red RS
CN Kayanol Red RS
CN Levanol Brilliant Red BB
CN Milling Fast Red R
CN Milling Fast Red RS
CN Milling Fast Red RX
CN Milling Red PRX
CN Multicuer Red BRX
CN Naphthalene Leather Red R
CN Optanol Red R
CN Pharmanil Red RB
CN Polar Red GBD
CN Polar Red R
CN Shikiso Acid Red RS
CN Sulfonine Red RS
CN Suminol Milling Red GRS
CN Suminol Red RS
CN Supranol Fast Red RX
CN Takaoka Acid Red RS
CN Triacid Fast Red GRS
MF C34 H26 N4 O8 S2 . 2 Na
LC STN Files: CA, CAOLD, CAPLUS, CHEMCATS, CHEMLIST, RTECS*, TOXCENTER, USPATFULL, USPATOLD
        (*File contains numerically searchable property data)
    Other Sources: DSL**, EINECS**, TSCA**
        (**Enter CHEMLIST File for up-to-date regulatory information)
CRN (25317-42-4)



●2 Na

21 REFERENCES IN FILE CA (1907 TO DATE)
21 REFERENCES IN FILE CAPLUS (1907 TO DATE)
2 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L7 ANSWER 28 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN
RN 2241-61-4 REGISTRY
ED Entered STN: 16 Nov 1984
CN Benz[b]indeno[1,2-d]pyran-3,6a,9,10(6H)-tetrol, 7,11b-dihydro-, tetraacetate, (6aS,11bR)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Benz[b]indeno[1,2-d]pyran-3,6a,9,10(6H)-tetrol, 7,11b-dihydro-, tetraacetate (7CI)
CN Benz[b]indeno[2,1-d]pyran-3,6a,9,10(6H)-tetrol, 7,10b-dihydro-, tetraacetate, (6aS-cis)-
OTHER NAMES:
CN BRX 019
CN Tetraacetylbrazilin
FS STEREOSEARCH
MF C24 H22 O9
LC STN Files: BEILSTEIN*, BIOSIS, CA, CAOLD, CAPLUS, CHEMCATS, MEDLINE, PROUSDDR, SYNTHLINE, TOXCENTER
(*File contains numerically searchable property data)

Absolute stereochemistry. Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

5 REFERENCES IN FILE CA (1907 TO DATE)
5 REFERENCES IN FILE CAPLUS (1907 TO DATE)
2 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L7 ANSWER 29 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN
RN 1658-56-6 REGISTRY
ED Entered STN: 16 Nov 1984
CN 1-Naphthalenesulfonic acid, 4-[2-(2-hydroxy-1-naphthalenyl)diazenyl]-, sodium salt (1:1) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 1-Naphthalenesulfonic acid, 4-[(2-hydroxy-1-naphthalenyl)azo]-, monosodium salt (9CI)
CN C.I. Acid Red 88, monosodium salt (8CI)
OTHER NAMES:
CN 11391 Red
CN 2-Naphthol Red J
CN Acid Cardinal G
CN Acid Fast Red A
CN Acid Leather Red ROC
CN Acid Red 88
CN Acid Red A
CN Acid Red A (Chinese)
CN Acid Red AV
CN Acid Red G
CN Acid Rose AV
CN Acid Scarlet G
CN Airedale Red A
CN Amacid Fast Red A
CN Ambicid Fast Red E
CN Anadurm Red A-ROC
CN Anthrosin BRX
CN Apollo Acid Rocceline
CN Atul Acid Fast Red A
CN Azo Acid Red GS
CN Basacid Red 340
CN Benzyl Red ROC
CN Benzyl Red S
CN Brasilan Red S
CN Bucacid Fast Red A
CN C.I. 15620
CN C.I. Acid Red 88
CN Calcocid Fast Red A
CN Cavalene Red A
CN Colacid Red AV
CN Colocid Fast Red A
CN Conacid Red MM
CN Daedo Acid Roccelline NS
CN Dai-ei Roccelline
CN Derma Fur Red R 150
CN Diacid Red A
CN Dinacid Fast Red A
CN Dyacid Red J
CN Dycosacid Red A
CN Eniacid Fast Red A
CN Eriosin Roccelline
CN Eriosin Roccelline SS
CN Ext D and C Red No. 8
CN Fabracid Red S-A
CN Fast Acid Red G
CN Fast Red A
CN Fast Red A (acid dye)
CN Fast Red AE
ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT - Use FCN, FIDE, or ALL for DISPLAY
DR 163442-07-7, 39309-87-0

MF C20 H14 N2 O4 S . Na
CI COM
LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN*, BIOSIS, CA, CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMLIST, CSCHEM, DETHERM*, IFICDB, IFIPAT, IFIUDB, MEDLINE, MSDS-OHS, PIRA, PROMT, RTECS*, TOXCENTER, USPAT2, USPATFULL, USPATOLD
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)
CRN (18268-54-7)



● Na

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

429 REFERENCES IN FILE CA (1907 TO DATE)
9 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
429 REFERENCES IN FILE CAPLUS (1907 TO DATE)
8 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L7 ANSWER 30 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN
RN 1326-85-8 REGISTRY
ED Entered STN: 16 Nov 1984
CN C.I. Sulphur Black 2 (8CI, 9CI) (CA INDEX NAME)
OTHER NAMES:
CN C.I. 53195
CN C.I. Sulfur Black 2
CN Calcogene Black 2R-CF
CN Calcogene Black RB-CF
CN Diresul Black 2R
CN Diresul Black 3R
CN Diresul Black EV-PL
CN Eclipse Deep Black BG
CN Fenoxyl Black 2R
CN Katigen Deep Black RRND-CF
CN Kayaku Sulphur Black BRX
CN Mitsui Sulphur Black ABR
CN Mitsui Sulphur Black BBRO
CN Mitsui Sulphur Black BR
CN Mitsui Sulphur Black R

CN Mitsui Sulphur Black RC
CN Nissen Black BRX
CN Sodyesul Black MCF
CN Solfo Black 3R
CN Solfo Black R
CN Sulfanol Black 2R
CN Sulfogene Carbon 4RCF
CN Sulfogene Carbon MCF
CN Sulfogene Carbon Supra CF Grains
CN Sulfogene Carbon T
CN Sulfogene Grey HlA grai
CN Sulfur Black 2
CN Sulfur Black 2RD
CN Sulfur Black 4RD
CN Sulfur Black DR
CN Sulfur Black RND
CN Sulphol Black BSP
CN Sulphol Black BSP Paste
CN Sulphol Black No. 44
CN Sulphol Black PG
CN Sulphol Black PXR Ex. Conc
CN Sulphol Black PXR Paste
CN Sulphol Black RS Grains
CN Sulphol Liquid Black QR
CN Sulphur Black 2
CN Thionol Black R
DEF This substance is identified in the COLOUR INDEX by Colour Index Constitution Number, C.I. 53195.
MF Unspecified
CI MAN
LC STN Files: CA, CAPLUS, CHEMCATS, CHEMLIST, TOXCENTER, USPAT2, USPATFULL
Other Sources: NDSL**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
11 REFERENCES IN FILE CA (1907 TO DATE)
11 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7 ANSWER 31 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN
RN 1064-48-8 REGISTRY
ED Entered STN: 16 Nov 1984
CN 2,7-Naphthalenedisulfonic acid, 4-amino-5-hydroxy-3-[2-(4-nitrophenyl)diazenyl]-6-(2-phenyldiazenyl)-, sodium salt (1:2) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 2,7-Naphthalenedisulfonic acid, 4-amino-5-hydroxy-3-[(4-nitrophenyl)azo]-6-(phenylazo)-, disodium salt (9CI)
CN Amido Black 10B (6CI)
OTHER NAMES:
CN Acid Black 1
CN Acid Black 10A
CN Acid Black 10B
CN Acid Black 10BA
CN Acid Black 10BN
CN Acid Black 10BX
CN Acid Black 12B
CN Acid Black 4BN
CN Acid Black 4BNU
CN Acid Black 8GB
CN Acid Black Base M
CN Acid Black BRX
CN Acid Black BX

CN Acid Black H
CN Acid Black JVS
CN Acid Blue Black
CN Acid Blue Black 10B
CN Acid Blue Black 10BX
CN Acid Blue Black B
CN Acid Blue Black BG
CN Acid Blue Black Double 600
CN Acid Blue Black Sh
CN Acid Leather Blue IGW
CN Acid Leather Dark Blue G
CN Acid Leather Fast Blue Black G
CN Acidal Black 10B
CN Acidal Black MV
CN Acidal Navy Blue 3BR
CN Aciderm Black E 10B
CN Acilan Black 10B
CN Airedale Black 2BG
CN Amacid Black 10BR
CN Amide Black 10B
CN Amido Black
CN Amido Blue Black 12B
CN Apollo Acid Blue Black 10B
CN Atul Acid Black 10BX
CN Atul Acid Black BX
CN Azanol Fast Acid Black 10B
CN Azo Dark Blue C 2B
CN Azo Dark Blue HR
CN Azo Dark Blue S
CN Azo Dark Blue SH
CN Best Acid Dark Blue B
CN Black 401
CN Blue Black 12B
CN Blue Black SX
CN Borunil Grey A 10B
ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT - Use FCN, FIDE, or ALL for DISPLAY
DR 12042-02-3, 68417-62-9, 84842-81-9, 86923-11-7, 31258-44-3
MF C22 H16 N6 O9 S2 . 2 Na
CI COM
LC STN Files: AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOSIS, BIOTECHNO, CA, CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMLIST, CSCHEM, EMBASE, IFICDB, IFIPAT, IFIUDB, MEDLINE, MSDS-OHS, PROMT, RTECS*, TOXCENTER, USPAT2, USPATFULL, USPATOLD
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)
CRN (3121-74-2)



●2 Na

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

925 REFERENCES IN FILE CA (1907 TO DATE)
5 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
926 REFERENCES IN FILE CAPLUS (1907 TO DATE)
10 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L7 ANSWER 32 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN
RN 147-14-8 REGISTRY
ED Entered STN: 16 Nov 1984
CN Copper, [29H,31H-phthalocyaninato(2-)-
κN29,κN30,κN31,κN32]-, (SP-4-1)- (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 29H,31H-Phthalocyanine, copper complex
CN 29H,31H-Phthalocyanine, copper deriv.
OTHER NAMES:
CN (Phthalocyaninato)copper
CN α-Copper phthalocyanine
CN α-Copper phthalocyanine blue
CN α-Phthalocyanine blue
CN β-Copper phthalocyanine blue
CN β-Phthalocyanine blue
CN ε-Copper phthalocyanine
CN 127EPS
CN 405D
CN 7075M
CN 79S26C
CN 79S26C chip
CN Accosperse Cyan Blue GT
CN Acnalin Supra Blue G
CN Acramin Blue F 3G
CN Akrochem 626
CN Aqualine Blue
CN Aquis BW 3571
CN Arlocyanine Blue PS
CN Aztech Chemisperse Cyan 1541
CN B 4G-KR
CN B 702W
CN B 705H
CN B 736
CN B 8M25
CN Bahama Blue BC
CN Bahama Blue BNC
CN Bahama Blue Lake NCNF
CN Bahama Blue WD
CN Bermuda Blue
CN BFD 1121
CN BGS 1
CN BGSG-C
CN BL 1531
CN Blue 7110V
CN Blue GLA
CN Blue GLA-SD
CN Blue GLSM
CN Blue Microdis
CN Blue phthalocyanaine α-form
CN Blue pigment
CN Blue Toner GTNF
CN BRS 1
CN BRX
CN BT 4651

CN C.I. 74160
CN C.I. Pigment Blue 15
CN C.I. Pigment Blue 15:1
ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT - Use FCN, FIDE, or ALL for DISPLAY
DR 807622-86-2, 819860-69-0, 819860-85-0, 878390-73-9, 924902-00-1, 12767-67-8, 10482-39-0, 11097-56-6, 11129-84-3, 177529-54-3, 177646-05-8, 158853-86-2, 172308-31-5, 172826-46-9, 53802-06-5, 57916-96-8, 57425-52-2, 55819-49-3, 59518-91-1, 59966-88-0, 64333-57-9, 95660-31-4, 95917-74-1, 96024-35-0, 104921-99-5, 51331-32-9, 115284-42-9, 60880-51-5, 60937-79-3, 61489-66-5, 61489-77-8, 61537-10-8, 109675-77-6, 109766-95-2, 66121-19-5, 37223-81-7, 69431-77-2, 78170-27-1, 78413-59-9, 85255-95-4, 85256-77-5, 92909-14-3, 90452-20-3, 34567-54-9, 39378-75-1, 39473-10-4, 53028-77-6, 175386-67-1, 184007-78-1, 209343-48-6, 211564-97-5, 211925-80-3, 213190-86-4, 244244-86-8, 345338-75-2, 392718-62-6, 681847-78-9
MF C32 H16 Cu N8
CI CCS, COM
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BIOSIS, BIOTECHNO, CA, CAOLD, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN, CSCHEM, CSNB, DETHERM*, EMBASE, GMELIN*, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, PIRA, PROMT, RTECS*, SPECINFO, TOXCENTER, USPAT2, USPATFULL, USPATOLD
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

17797 REFERENCES IN FILE CA (1907 TO DATE)
1297 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
17840 REFERENCES IN FILE CAPLUS (1907 TO DATE)
134 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	85.59	300.80

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-6.40

FILE 'CAPLUS' ENTERED AT 13:20:23 ON 17 NOV 2008

FILE COVERS 1907 - 17 Nov 2008 VOL 149 ISS 21
FILE LAST UPDATED: 16 Nov 2008 (20081116/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/legal/infopolicy.html

=> s (l5 of l7 or arimoclomol) and (aml or sclerosis)
MISSING OPERATOR L5 OF
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> s (l5 or l7 or arimoclomol) and (aml or sclerosis)
10 L5

```
         19197 L7
             9 ARIMOCLOMOL
          8038 AML
           253 AMLS
          8079 AML
                 (AML OR AMLS)
         33016 SCLEROSIS
            30 SCLEROSES
         33031 SCLEROSIS
                 (SCLEROSIS OR SCLEROSES)
L8          11 (L5 OR L7 OR ARIMOCLOMOL) AND (AML OR SCLEROSIS)

=> d l8 ibib abs 1-11

L8   ANSWER 1 OF 11  CAPLUS  COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:        2008:1320737  CAPLUS
TITLE:                   Late stage treatment with arimoclomol delays
                         disease progression and prevents protein aggregation
                         in the SOD1G93A mouse model of ALS
AUTHOR(S):               Kalmar, Bernadett; Novoselov, Sergey; Gray, Anna;
                         Cheetham, Michael E.; Margulis, Boris; Greensmith,
                         Linda
CORPORATE SOURCE:        Institute of Neurology, University College London,
                         London, UK
SOURCE:                  Journal of Neurochemistry (2008), 107(2), 339-350
                         CODEN: JONRA9; ISSN: 0022-3042
PUBLISHER:               Wiley-Blackwell
DOCUMENT TYPE:           Journal
LANGUAGE:                English
AB   Amyotrophic lateral sclerosis (ALS) is a progressive
     neurodegenerative disorder characterized by motoneuron degeneration,
     resulting in muscle paralysis and death, typically within 1-5 years of
     diagnosis.  Although the pathogenesis of ALS remains unclear, there is
     evidence for the involvement of proteasome dysfunction and heat shock
     proteins in the disease.  We have previously shown that treatment with a
     co-inducer of the heat shock response called arimoclomol is
     effective in the SODG93A mouse model of ALS, delaying disease progression
     and extending the lifespan of SODG93A mice.  However, this previous study
     only examined the effects arimoclomol when treatment was initiated
     in pre- or early symptomatic stages of the disease.  Clearly, to be of
     benefit to the majority of ALS patients, any therapy must be effective
     after symptom onset.  In order to establish whether post-symptomatic
     treatment with arimoclomol is effective, in this study we
     carried out a systematic assessment of different treatment regimes in
     SODG93A mice.  Treatment with arimoclomol from early (75 days)
     or late (90 days) symptomatic stages significantly improved muscle
     function.  Treatment from 75 days also significantly increased the
     lifespan of SODG93A mice, although treatment from 90 days has no
     significant effect on lifespan.  The mechanism of action of
     arimoclomol involves potentiation of the heat shock response, and
     treatment with arimoclomol increased Hsp70 expression.
     Interestingly, this up-regulation in Hsp70 was accompanied by a decrease
     in the number of ubiquitinpos. aggregates in the spinal cord of treated
     SODG93A mice, suggesting that arimoclomol directly effects
     protein aggregation and degradation

L8   ANSWER 2 OF 11  CAPLUS  COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:        2008:918262  CAPLUS
DOCUMENT NUMBER:         149:258394
TITLE:                   Arimoclomol at dosages up to 300 Mg/day is
                         well tolerated and safe in amyotrophic lateral
                         sclerosis
```

AUTHOR(S): Cudkowicz, Merit E.; Shefner, Jeremy M.; Simpson, Elizabeth; Grasso, Daniela; Yu, Hong; Zhang, Hui; Shui, Amy; Schoenfeld, David; Brown, Robert H.; Wieland, Scott; Barber, Jack R.
CORPORATE SOURCE: NORTHEAST ALS CONSORTIUM, Neurology Clinical Trials Unit, Massachussets General Hospital, Charlestown, MA, 02129, USA
SOURCE: Muscle & Nerve (2008), 38(1), 837-844
CODEN: MUNEDE; ISSN: 0148-639X
PUBLISHER: John Wiley & Sons, Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Arimoclomol is an investigational drug for amyotrophic lateral sclerosis (ALS) that amplifies heat shock protein gene expression during cell stress. The objectives of the present study were to assess the safety, tolerability, and pharmacokinetics of arimoclomol in ALS. Eighty-four participants with ALS received arimoclomol at one of three oral doses (25, 50, or 100 mg three times daily) or placebo. The primary outcome measure was safety and tolerability. A subset of 44 participants provided serum and cerebrospinal fluid (CSF) samples for pharmacokinetic anal. Participants who completed 12 wk of treatment could enroll in a 6-mo open-label study. Arimoclomol at doses up to 300 mg/day was well tolerated and safe. Arimoclomol resulted in dose-linear pharmacol. exposures and the half-life did not change with continued treatment. Arimoclomol CSF levels increased with dose. Arimoclomol was shown to be safe, and it crosses the blood-brain barrier. Serum pharmacokinetic profiles support dosing of three times per day. An efficacy study in ALS is planned.

REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 3 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2008:223578 CAPLUS
DOCUMENT NUMBER: 148:269430
TITLE: Methods and compositions for the treatment of neurodegenerative disorders such as Huntington's disease
INVENTOR(S): Jin, Xiaowei; Wilson, Amy Beth; Staunton, Jane; MacDonald, Douglas
PATENT ASSIGNEE(S): Combinatorx, Incorporated, USA; Chdi, Inc.
SOURCE: PCT Int. Appl., 127pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008021210	A2	20080221	WO 2007-US17751	20070810
WO 2008021210	A3	20081030		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,

BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

US 20080044390	A1	20080221	US 2007-891552		20070810
PRIORITY APPLN. INFO.:			US 2006-837448P	P	20060811
			US 2007-898479P	P	20070131
			US 2007-925777P	P	20070423
			US 2007-958832P	P	20070709

AB The present invention features compns., kits, and methods for treating, preventing, and ameliorating neurodegenerative disorders, e.g., Huntington's disease (HD). Screening methods for identifying candidate compds. that treat, prevent, or ameliorate neurodegenerative disorders, e.g., HD, are provided. Thus, N-terminal fragment of Htt has been shown to form protein aggregates in the nucleus, cytoplasm and processes of neurons in human HD patients and in HD animal models, as well as in many cellular models. Because of their similarities to neurons, rat pheochromocytoma PC12 cells have provided a useful model for studying neuronal cell biol.; in addition, PC12 cells are readily transfected, selected and cloned. In order to perform screening according to a method of the present invention, PC12 cells were obtained that stably incorporated a plasmid that inducibly expresses a toxic expanded polyglutamine (103 glutamine) form of exon 1 of Htt, fused to the marker EGFP. Using the engineered PC12/HttN90Q103 cell line, a high throughput assay to screen small mols. for their ability to prevent mutant Htt exon 1-induced cell death was developed and optimized.

L8 ANSWER 4 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER:	2007:1424894 CAPLUS
DOCUMENT NUMBER:	148:492092
TITLE:	Heat shock proteins and protection of the nervous system
AUTHOR(S):	Brown, Ian R.
CORPORATE SOURCE:	Center for the Neurobiology of Stress, University of Toronto at Scarborough, Toronto, ON, Can.
SOURCE:	Annals of the New York Academy of Sciences (2007), 1113(Stress Responses in Biology and Medicine), 147-158 CODEN: ANYAA9; ISSN: 0077-8923
PUBLISHER:	Blackwell Publishing, Inc.
DOCUMENT TYPE:	Journal; General Review
LANGUAGE:	English

AB A review. Manipulation of the cellular stress response offers strategies to protect brain cells from damage induced by ischemia and neurodegenerative diseases. Overexpression of Hsp70 reduced ischemic injury in the mammalian brain. Investigation of the domains within Hsp70 that confers ischemic neuroprotection revealed the importance of the carboxyl-terminal domain. Arimoclomol, a coinducer of heat shock proteins, delayed progression of amyotrophic lateral sclerosis (ALS) in a mouse model in which motor neurons in the spinal cord and motor cortex degenerate. Celastrol, a promising candidate as an agent to counter neurodegenerative diseases, induced expression of a set of Hsps in differentiated neurons grown in tissue culture. Heat shock "preconditioning" protected the nervous system at the functional level of the synapse and selective overexpression of Hsp70 enhanced the level of synaptic protection. Following hyperthermia, constitutively expressed Hsc70 increased in synapse-rich areas of the brain where it assocs. with Hsp40 to form a complex that can refold denatured proteins. Stress tolerance in neurons is not solely dependent on their own Hsps but can be supplemented by Hsps from adjacent glial cells. Hence, application of exogenous Hsps at neural injury sites is an effective strategy to maintain neuronal viability.

REFERENCE COUNT: 72 THERE ARE 72 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 5 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:1207486 CAPLUS
DOCUMENT NUMBER: 147:466838
TITLE: Identifying signal transduction pathways that mediate nervous system plasticity by gene expression profiling and the selection of pathway modulators for therapeutic use
INVENTOR(S): Sur, Mriganka; Tropea, Daniela; Kreiman, Gabriel
PATENT ASSIGNEE(S): Massachusetts Institute of Technology, USA
SOURCE: PCT Int. Appl., 407pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007120847	A2	20071025	WO 2007-US9172	20070412

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2006-792275P P 20060414
AB Methods for identifying genes and pathways involved in neuronal plasticity by anal. of the effects of deprivation and stimulation on patterns of gene expression in nervous tissue are described. The invention applies some of these methods to identify genes that are differentially regulated in at least a portion of the nervous system of an individual subjected to conditions known to result in altered nervous system plasticity, i.e., dark rearing (DR) or monocular deprivation (MD). The genes are targets for pharmacol. agents that modify plasticity and candidate agents modifying neuronal plasticity are identified. The invention also identifies biol. pathways that are enriched in the products of genes that are differentially regulated under conditions known to result in altered nervous system plasticity. The methods and compns. may be administered to a subject suffering from damage to the nervous system or from a neuropsychiatric disorder in order to enhance recovery, reorganization, or function of the nervous system. The methods optionally include administering a proteolysis-enhancing agent to the subject.

L8 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:711978 CAPLUS
DOCUMENT NUMBER: 147:377138
TITLE: Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis
AUTHOR(S): Bedlack, Richard S.; Traynor, Bryan J.; Cudkowicz, Merit E.
CORPORATE SOURCE: Duke University Medical Center, Durham, NC, USA
SOURCE: Expert Opinion on Emerging Drugs (2007), 12(2), 229-252
CODEN: EOEDA3
PUBLISHER: Informa Healthcare

DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
AB A review. It has been > 130 years since the first description of the upper and lower motor neuron disease called amyotropic lateral sclerosis (ALS). Sadly, there has been little change in the long interval over which this disease is diagnosed, or in its poor prognosis. Significant gains have been made, however, in understanding its pathophysiol. and in symptomatic care. Disease-causing mutations have been identified and used to create animal models. Other identified mutations may increase susceptibility and cause disease only in a particular environment and at a particular age. A number of 'downstream' mol. pathways have been implicated, including transcriptional disturbances, protein aggregation, excitotoxicity, mitochondrial dysfunction, oxidative stress, neuroinflammation, cytoskeletal and axonal transport derangements, growth factor dysregulation and apoptosis. This knowledge has led to an impressive pipeline of candidate therapies that offer hope for finally being able to alter ALS disease progression. These are described and prioritized herein, and suggestions are offered for efficiently sifting through them.
REFERENCE COUNT: 148 THERE ARE 148 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 7 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:598700 CAPLUS
DOCUMENT NUMBER: 145:499471
TITLE: Neuroprotective agents for clinical trials in ALS
AUTHOR(S): Traynor, B. J.; Bruijn, L.; Conwit, R.; Beal, F.; O'Neill, G.; Fagan, S. C.; Cudkowicz, M. E.
CORPORATE SOURCE: Neurology Clinical Trials Unit, Department of Neurology, Massachusetts General Hospital, Boston, MA, USA
SOURCE: Neurology (2006), 67(1), 20-27
CODEN: NEURAI; ISSN: 0028-3878
PUBLISHER: Lippincott Williams & Wilkins
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
AB A review. Background: Riluzole is currently the only Food and Drug Administration-approved treatment for ALS, but its effect on survival is modest. Objective: To identify potential neuroprotective agents for testing in phase III clin. trials and to outline which data need to be collected for each drug. Methods: The authors identified 113 compds. by inviting input from academic clinicians and researchers and via literature review to identify agents that have been tested in ALS animal models and in patients with ALS. The list was initially narrowed to 24 agents based on an evaluation of scientific rationale, toxicity, and efficacy in previous animal and human studies. These 24 drugs underwent more detailed pharmacol. evaluation. Results: Twenty drugs were selected as suitable for further development as treatments for patients with ALS. Talampanel and tamoxifen have completed early phase II trials and have demonstrated preliminary efficacy. Other agents (ceftriaxone, minocycline, ONO-2506, and IGF-1 polypeptide) are already in phase III trials involving large nos. of patients with ALS. Remaining agents (AEOL 10150, arimoclomol, celastrol, coenzyme Q10, copaxone, IGF-1-viral delivery, memantine, NAALADase inhibitors, nimesulide, scriptaid, sodium phenylbutyrate, thalidomide, trehalose) require addnl. preclin. animal data, human toxicity and pharmacokinetic data including CNS penetration prior to proceeding to large scale phase III human testing. Further development of riluzole analogs should be considered. Conclusions: Several potential neuroprotective compds., representing a wide range of mechanisms, are available and merit further investigation in ALS.
REFERENCE COUNT: 86 THERE ARE 86 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 8 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:409316 CAPLUS
DOCUMENT NUMBER: 142:441894
TITLE: Use of a hydroximic acid halide derivative in the treatment of neurodegenerative diseases
INVENTOR(S): Greensmith, Linda; Burnstock, Geoffrey; Urbanics, Rudolf
PATENT ASSIGNEE(S): Biorex Kutato es Fejlesztoe Rt., Hung.
SOURCE: PCT Int. Appl., 24 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005041965	A1	20050512	WO 2004-HU98	20041025
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004285343	A1	20050512	AU 2004-285343	20041025
CA 2544332	A1	20050512	CA 2004-2544332	20041025
EP 1696922	A1	20060906	EP 2004-791657	20041025
EP 1696922	B1	20080924		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
BR 2004015625	A	20061212	BR 2004-15625	20041025
CN 1901913	A	20070124	CN 2004-80039619	20041025
JP 2007509920	T	20070419	JP 2006-537449	20041025
AT 409038	T	20081015	AT 2004-791657	20041025
MX 2006PA04814	A	20061211	MX 2006-PA4814	20060428
NO 2006002401	A	20060727	NO 2006-2401	20060526
IN 2006KN01464	A	20070504	IN 2006-KN1464	20060530
US 20080039497	A1	20080214	US 2007-582124	20070510
PRIORITY APPLN. INFO.:			HU 2003-3584 A	20031030
			WO 2004-HU98 W	20041025

AB The invention relates to the use of a chemical substance selected from the group consisting of N-[2-hydroxy-3-(1-piperidinyl)-propoxyl]-pyridine-1-oxide-3-carboximidoyl chloride, the optically active enantiomers and the mixts. of enantiomers thereof and pharmaceutically acceptable salts of the racemic and optically active compds. in the preparation of a pharmaceutical composition for the treatment or prevention of neurodegenerative diseases.
REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 9 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:263763 CAPLUS
DOCUMENT NUMBER: 140:399884
TITLE: Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice

AUTHOR(S): Kieran, Dairin; Kalmar, Bernadett; Dick, James R. T.; Riddoch-Contreras, Joanna; Burnstock, Geoffrey; Greensmith, Linda
CORPORATE SOURCE: The National Hospital for Neurology and Neurosurgery, Institute of Neurology, Sobell Department of Motor Neuroscience and Movement Disorders, The Graham Watts Laboratory, University College London, London, WC1N 3BG, UK
SOURCE: Nature Medicine (New York, NY, United States) (2004), 10(4), 402-405
CODEN: NAMEFI; ISSN: 1078-8956
PUBLISHER: Nature Publishing Group
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative condition in which motoneurons of the spinal cord and motor cortex die, resulting in progressive paralysis. This condition has no cure and results in eventual death, usually within 1-5 yr of diagnosis. Although the specific etiol. of ALS is unknown, 20% of familial cases of the disease carry mutations in the gene encoding Cu/Zn superoxide dismutase-1 (SOD1). Transgenic mice overexpressing human mutant SOD1 have a phenotype and pathol. that are very similar to that seen in human ALS patients. Here we show that treatment with arimoclomol, a coinducer of heat shock proteins (HSPs), significantly delays disease progression in mice expressing a SOD1 mutant in which glycine is substituted with alanine at position 93 (SOD1G93A). Arimoclomol-treated SOD1G93A mice show marked improvement in hind limb muscle function and motoneuron survival in the later stages of the disease, resulting in a 22% increase in lifespan. Pharmacol. activation of the heat shock response may therefore be a successful therapeutic approach to treating ALS, and possibly other neurodegenerative diseases.
REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 10 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1971:401127 CAPLUS
DOCUMENT NUMBER: 75:1127
ORIGINAL REFERENCE NO.: 75:187a,190a
TITLE: Histochemistry of myelin. XII. Anionic staining of myelin basic proteins for histology, electrophoresis, and electron microscopy
AUTHOR(S): Adams, Colin W. M.; Bayliss, Olga B.; Hallpike, J. F.; Turner, D. R.
CORPORATE SOURCE: Med. Sch., Guy's Hosp., London, UK
SOURCE: Journal of Neurochemistry (1971), 18(3), 389-94
CODEN: JONRA9; ISSN: 0022-3042
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Phosphotungstic acid hematoxylin, trypan blue, and amido black techniques were developed as anionic dye methods for staining myelin basic proteins. All methods displayed central and peripheral nervous system myelin in histochem. prepns. and stained brain basic proteins in electrophoretic polyacrylamide gels: phosphotungstic acid hematoxylin appeared to be the most selective of these techniques. Electron photomicrographs of peripheral nerve stained by phosphotungstic acid hematoxylin showed that the major part of myelin basic protein is located in the period dense line. The basic proteins stained by phosphotungstic acid hematoxylin showed an early loss in rat sciatic nerve undergoing Wallerian degeneration and had completely disappeared from the center of 20 plaques of multiple sclerosis.

L8 ANSWER 11 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1959:73788 CAPLUS
DOCUMENT NUMBER: 53:73788
ORIGINAL REFERENCE NO.: 53:13384b
TITLE: Histochemistry and classification of the Pelizaeus-Merzbacher disease
AUTHOR(S): Seitelberger, Franz
CORPORATE SOURCE: Univ. Vienna, Munich, Germany
SOURCE: Cerebral Lipidoses (J. N. Cumings and A Lowenthal, editors. Charles C Thomas, publisher) (1957), Volume Date 1955, (Symposium, Antwerp), 92-7
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
AB Review with reference.

=>
Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:ssptacrs1614

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	DEC 01	ChemPort single article sales feature unavailable
NEWS 3	JAN 06	The retention policy for unread STNmail messages will change in 2009 for STN-Columbus and STN-Tokyo
NEWS 4	JAN 07	WPIDS, WPINDEX, and WPIX enhanced Japanese Patent Classification Data
NEWS 5	FEB 02	Simultaneous left and right truncation (SLART) added for CERAB, COMPUAB, ELCOM, and SOLIDSTATE
NEWS 6	FEB 02	GENBANK enhanced with SET PLURALS and SET SPELLING
NEWS 7	FEB 06	Patent sequence location (PSL) data added to USGENE
NEWS 8	FEB 10	COMPENDEX reloaded and enhanced
NEWS 9	FEB 11	WTEXTILES reloaded and enhanced
NEWS 10	FEB 19	New patent-examiner citations in 300,000 CA/CAplus patent records provide insights into related prior art
NEWS 11	FEB 19	Increase the precision of your patent queries -- use terms from the IPC Thesaurus, Version 2009.01
NEWS 12	FEB 23	Several formats for image display and print options discontinued in USPATFULL and USPAT2
NEWS 13	FEB 23	MEDLINE now offers more precise author group fields and 2009 MeSH terms
NEWS 14	FEB 23	TOXCENTER updates mirror those of MEDLINE - more precise author group fields and 2009 MeSH terms
NEWS 15	FEB 23	Three million new patent records blast AEROSPACE into STN patent clusters
NEWS 16	FEB 25	USGENE enhanced with patent family and legal status display data from INPADOCDB
NEWS 17	MAR 06	INPADOCDB and INPAFAMDB enhanced with new display formats
NEWS 18	MAR 11	EPFULL backfile enhanced with additional full-text applications and grants

```
 NEWS 19  MAR 11  ESBIOBASE reloaded and enhanced
 NEWS 20  MAR 20  CAS databases on STN enhanced with new super role
                  for nanomaterial substances
 NEWS 21  MAR 23  CA/CAplus enhanced with more than 250,000 patent
                  equivalents from China
 NEWS 22  MAR 30  IMSPATENTS reloaded and enhanced
 NEWS 23  APR 03  CAS coverage of exemplified prophetic substances
                  enhanced
 NEWS 24  APR 07  STN is raising the limits on saved answers

 NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
              AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN customer
  agreement.  This agreement limits use to scientific research.  Use
  for software development or design, implementation of commercial
  gateways, or use of CAS and STN data in the building of commercial
  products is prohibited and may result in loss of user privileges
  and other penalties.

* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 14:57:49 ON 22 APR 2009

=> file registry caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.22       0.22

FILE 'REGISTRY' ENTERED AT 14:58:11 ON 22 APR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

FILE 'CAPLUS' ENTERED AT 14:58:11 ON 22 APR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

=> file registry
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.98       1.20

FILE 'REGISTRY' ENTERED AT 14:58:22 ON 22 APR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   21 APR 2009  HIGHEST RN 1137826-72-2
DICTIONARY FILE UPDATES:  21 APR 2009  HIGHEST RN 1137826-72-2
```

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

```
=> e ariclomol
E1            1     ARICIRESIN/BI
E2            1     ARICIRESINOL/BI
E3            0 --> ARICLOMOL/BI
E4            2     ARICOL/BI
E5            2     ARICOLA/BI
E6            2     ARICRKSARI/BI
E7            3     ARICYL/BI
E8            9     ARID/BI
E9            2     ARID1/BI
E10           2     ARID1A/BI
E11           2     ARID1B/BI
E12           8     ARID2/BI

=> e arimoclomol
E1            1     ARIMIDS/BI
E2            1     ARIMOCLOM/BI
E3            1 --> ARIMOCLOMOL/BI
E4            2     ARIMOL/BI
E5            2     ARIMOSA/BI
E6            1     ARIMOTO/BI
E7          130     ARIN/BI
E8           17     ARINA/BI
E9           13     ARINAE/BI
E10           1     ARINAMINE/BI
E11           4     ARINATE/BI
E12          56     ARINE/BI

=> s e3
L1            1 ARIMOCLOMOL/BI

=> d l1

L1   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2009 ACS on STN
RN   289893-25-0  REGISTRY
ED   Entered STN:  21 Sep 2000
CN   3-Pyridinecarboximidoyl chloride, N-[(2R)-2-hydroxy-3-(1-
     piperidinyl)propoxy]-, 1-oxide  (CA INDEX NAME)
OTHER NAMES:
CN   Arimoclomol
FS   STEREOSEARCH
MF   C14 H20 Cl N3 O3
CI   COM
SR   CA
LC   STN Files:   ADISINSIGHT, CA, CAPLUS, CBNB, EMBASE, IMSRESEARCH, PHAR,
       PROUSDDR, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL

Absolute stereochemistry.
```

Double bond geometry unknown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

14 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
14 REFERENCES IN FILE CAPLUS (1907 TO DATE)

```
=> file caplus embase biosis
COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                     ENTRY    SESSION
FULL ESTIMATED COST                                  12.68      13.88

FILE 'CAPLUS' ENTERED AT 15:04:53 ON 22 APR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 15:04:53 ON 22 APR 2009
Copyright (c) 2009 Elsevier B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 15:04:53 ON 22 APR 2009
Copyright (c) 2009 The Thomson Corporation

=> s l1 or (arimoclomol or (brx (a) 220)
UNMATCHED LEFT PARENTHESIS 'OR (ARIMOCLOMO'
The number of right parentheses in a query must be equal to the
number of left parentheses.

=> s l1 or (arimoclomol or (brx (a) 220))
L2          80 L1 OR (ARIMOCLOMOL OR (BRX (A) 220))

=> dup rem l2
PROCESSING COMPLETED FOR L2
L3          62 DUP REM L2 (18 DUPLICATES REMOVED)

=> s l3 and @py<=2004
'2004' NOT A VALID FIELD CODE
'2004' NOT A VALID FIELD CODE
'2004' NOT A VALID FIELD CODE
L4           0 L3 AND @PY<=2004

=> s l3 and py<=2004
L5          14 L3 AND PY<=2004

=> d l5 ibib abs 1-14

L5   ANSWER 1 OF 14  CAPLUS  COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER:        2004:263763  CAPLUS
DOCUMENT NUMBER:         140:399884
TITLE:                   Treatment with arimoclomol, a coinducer of
```

heat shock proteins, delays disease progression in ALS mice

AUTHOR(S): Kieran, Dairin; Kalmar, Bernadett; Dick, James R. T.; Riddoch-Contreras, Joanna; Burnstock, Geoffrey; Greensmith, Linda

CORPORATE SOURCE: The National Hospital for Neurology and Neurosurgery, Institute of Neurology, Sobell Department of Motor Neuroscience and Movement Disorders, The Graham Watts Laboratory, University College London, London, WC1N 3BG, UK

SOURCE: Nature Medicine (New York, NY, United States) (2004), 10(4), 402-405
CODEN: NAMEFI; ISSN: 1078-8956

PUBLISHER: Nature Publishing Group

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative condition in which motoneurons of the spinal cord and motor cortex die, resulting in progressive paralysis. This condition has no cure and results in eventual death, usually within 1-5 yr of diagnosis. Although the specific etiol. of ALS is unknown, 20% of familial cases of the disease carry mutations in the gene encoding Cu/Zn superoxide dismutase-1 (SOD1). Transgenic mice overexpressing human mutant SOD1 have a phenotype and pathol. that are very similar to that seen in human ALS patients. Here we show that treatment with arimoclomol, a coinducer of heat shock proteins (HSPs), significantly delays disease progression in mice expressing a SOD1 mutant in which glycine is substituted with alanine at position 93 (SOD1G93A). Arimoclomol-treated SOD1G93A mice show marked improvement in hind limb muscle function and motoneuron survival in the later stages of the disease, resulting in a 22% increase in lifespan. Pharmacol. activation of the heat shock response may therefore be a successful therapeutic approach to treating ALS, and possibly other neurodegenerative diseases.

REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:100113 CAPLUS

DOCUMENT NUMBER: 141:17416

TITLE: The effect of treatment with BRX-220, a co-inducer of heat shock proteins, on sensory fibers of the rat following peripheral nerve injury

AUTHOR(S): Kalmar, B.; Greensmith, L.; Malcangio, M.; McMahon, S. B.; Csermely, P.; Burnstock, G.

CORPORATE SOURCE: Sobell Department of Motor Neuroscience and Movement Disorders, Institute of Neurology, London, WC1N 3BG, UK

SOURCE: Experimental Neurology (2003), 184(2), 636-647
CODEN: EXNEAC; ISSN: 0014-4886

PUBLISHER: Elsevier Science

DOCUMENT TYPE: Journal

LANGUAGE: English

AB In this study, we examined the effect BRX-220, a co-inducer of heat shock proteins, in injury-induced peripheral neuropathy. Following sciatic nerve injury in adult rats and treatment with BRX-220, the following features of the sensory system were studied: (a) expression of calcitonin gene-related peptide (CGRP); (b) binding of isolectin B4 (IB4) in dorsal root ganglia (DRG) and spinal cord; (c) stimulation-evoked release of substance P (SP) in an in vitro spinal cord preparation and (d) nociceptive responses of partially denervated rats. BRX-220 partially reverses

axotomy-induced changes in the sensory system. In vehicle-treated rats there is a decrease in IB4 binding and CGRP expression in injured neurons, while in BRX-220-treated rats these markers were better preserved. Thus, 7.0 ± 0.6% of injured DRG neurons bound IB4 in vehicle-treated rats compared to 14.4 ± 0,9% in BRX-220-treated animals. Similarly, 4.5 ± 0.5% of DRG neurons expressed CGRP in the vehicle-treated group, whereas 9.0 ± 0.3% were pos. in the BRX-220-treated group. BRX-220 also partially restored SP release from spinal cord sections to elec. stimulation of primary sensory neurons. Behavioral tests carried out on partially denervated animals showed that BRX-220 treatment did not prevent the emergence of mech. or thermal hyperalgesia. However, oral treatment for 4 wk lead to reduced pain-related behavior suggesting either slowly developing analgesic actions or enhancement of recovery processes. Thus, the morphol. improvement seen in sensory neuron markers was accompanied by restored functional activity. Therefore, treatment with BRX-220 promotes restoration of morphol. and functional properties in the sensory system following peripheral nerve injury.

REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 14 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:587024 CAPLUS

DOCUMENT NUMBER: 138:130888

TITLE: Effect of BRX-220 against peripheral neuropathy and insulin resistance in diabetic rat models

AUTHOR(S): Kurthy, Maria; Mogyorosi, Tamas; Nagy, Karoly; Kukorelli, Tibor; Jednakovits, Andrea; Talosi, Laszlo; Biro, Katalin

CORPORATE SOURCE: Biorex Research and Development Company, Veszprem, Hung.

SOURCE: Annals of the New York Academy of Sciences (2002), 967(Lipids and Insulin Resistance), 482-489
CODEN: ANYAA9; ISSN: 0077-8923

PUBLISHER: New York Academy of Sciences

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Bimoclomol (BML), a symptomatic antidiabetic agent, was developed by Biorex R&D Co. to treat diabetic neuropathy and retinopathy. BRX-220, an orally active member of the BRX family, was developed to treat diabetic complications and insulin resistance (IR) as a follow-up compound The effect of BRX-220 on peripheral neuropathy was examined in rats with diabetes (type 1) induced by administration of a β-cell toxin, streptozotocin (STZ, 45 mg/kg iv). Nerve functions were evaluated by electrophysiol. measurements of muscle motor and sensory nerve conduction velocities (MNCV and SNCV, resp.). MNCV and SNCV decreased in diabetic rats by 25%. A 1-mo preventive treatment with BRX-220 (2.5, 5, 10, and 20 mg/kg po) dose-dependently improved diabetes-related deficits in MNCV (51.3, 71.3, 86.1, and 91.3%) and SNCV (48.9, 68.5, 86.1, and 93.2%). Insulin sensitivity was measured using the insulin tolerance test (ITT), both in STZ diabetic and in Zucker diabetic fatty (ZDF) rats (model of type 2 diabetes). Severe IR was detected in STZ diabetic and ZDF rats. This resistance was significantly reduced by BRX-220 treatment.

REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 14 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:587016 CAPLUS

DOCUMENT NUMBER: 138:130887
TITLE: Comparison of the extrapancreatic action of BRX-220 and pioglitazone in the high-fat diet-induced insulin resistance
AUTHOR(S): Sebokova, Elena; Kurthy, Maria; Mogyorosi, T.; Nagy, Karoly; Demcakova, Edita; Ukropec, Jozef; Koranyi, Laszlo; Klimes, Iwar
CORPORATE SOURCE: Diabetes and Nutrition Research Laboratory, Institute of Experimental Endocrinology, Slovak Academy of Sciences, Bratislava, SK-83306, Slovakia
SOURCE: Annals of the New York Academy of Sciences (2002), 967(Lipids and Insulin Resistance), 424-430
CODEN: ANYAA9; ISSN: 0077-8923
PUBLISHER: New York Academy of Sciences
DOCUMENT TYPE: Journal
LANGUAGE: English
AB A new Biorex mol., BRX-220, was shown to be effective in animal models of diabetic neuro- and retinopathy. Recent in vitro studies showed that it might also have an insulin-sensitizing action. Therefore, the effect of BRX-220 on insulin sensitivity was compared with the action of pioglitazone (PGZ) in high fat (HF) diet-induced insulin resistance (IR) of rats. Methods-Male Wistar rats were fed for 3 wk a standard chow (PD) or the HF (70-cal%) diet. The HF-fed rats were also given daily BRX-220 (20 mg/kg BW) or PGZ (6 mg/kg BW) by gavage. In vivo insulin action was assessed by the euglycemic hyperinsulinemic clamp. Glucose, insulin, FFA, triglyceride (TG), and glycerol levels in blood were also measured, as well as tissue TG content. Results-Increased levels of fed TG in circulation after HF diet (PD: 2.0 vs. HF: 5.0 mmol/L) were partially corrected by BRX-220 (HF+BRX: 3.8) and normalized by PGZ (HF+PGZ: 2.6). Both mols. prevented the increase in fed serum FFA levels after HF diet (PD: 0.5; HF: 1.8±0.2 mmol/L), with a more pronounced effect of PGZ (HF+BRX: 1.2; HF+PGZ: 0.7). Tissue TG levels increased significantly in response to HF feeding in both liver (HF: 16; PD: 6.4 μmol/g) and skeletal muscle (HF: 7.7; PD: 2.4). This increase was completely normalized by both agents in the liver (HF+BRX: 8.8; HF+PGZ: 8.8), and only partially in the skeletal muscles. HF diet-induced in vivo IR (PD: 25.4; HF: 15.7 mg/kg/min) was significantly reduced by BRX -220 (HF+BRX: 18.7) and PGZ (HF+PGZ: 22.8) treatment. Conclusions-(1) Subchronic administration of BRX-220 leads to an improvement of in vivo insulin action. (2) This insulin-sensitizing effect is, however, not as pronounced as that of PGZ. (3) It is accompanied by a decrease of circulating TG and FFA levels in the postprandial state and (4) by lower TG content in liver and skeletal muscle.
REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 5 OF 14 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2002:496814 CAPLUS
DOCUMENT NUMBER: 137:362925
TITLE: Upregulation of Heat Shock Proteins Rescues Motoneurones from Axotomy-Induced Cell Death in Neonatal Rats
AUTHOR(S): Kalmar, B.; Burnstock, G.; Vrbova, G.; Urbanics, R.; Csermely, P.; Greensmith, L.
CORPORATE SOURCE: Sobell Department of Motor Neuroscience and Movement Disorders, Institute of Neurology, London, WC1N 3BG, UK
SOURCE: Experimental Neurology (2002), 176(1), 87-97
CODEN: EXNEAC; ISSN: 0014-4886

PUBLISHER: Elsevier Science
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Heat shock proteins (hsps) are induced in a variety of cells following periods of stress, where they promote cell survival. In this study, we examined the effect of upregulating hsp expression by treatment with BRX-220, a co-inducer of hsps, on the survival of injured motoneurones. Following sciatic nerve crush at birth, rat pups were treated daily with BRX-220. The expression of hsp70 and hsp90, motoneurone survival, and muscle function was examined at various intervals later and the number of functional motor units was assessed by in vivo isometric tension recordings. Fourteen days after injury, significantly more motoneurones survived in the BRX-220 -treated group (39 ± 2.8%) compared to the saline-treated group (21 ± 1.7%). Moreover, in the BRX-220-treated group no further loss of motoneurones occurred, so that at 10 wk 42 ± 2.1% of motoneurones survived compared to 15 ± 0.6% in the untreated group. There were also more functional motor units in the hindlimb muscles of BRX-220-treated animals. In addition, treatment with BRX-220 resulted in a significant increase in the expression of hsp70 and hsp90 in glia and neurons. Thus, treatment with BRX-220, a co-inducer of hsps, protects motoneurones from axotomy-induced cell death.
REFERENCE COUNT: 52 THERE ARE 52 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 6 OF 14 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2002:418232 CAPLUS
DOCUMENT NUMBER: 138:49725
TITLE: Nontoxic heat shock protein coinducer BRX-220 protects against acute pancreatitis in rats
AUTHOR(S): Rakonczay, Zoltan; Ivanyi, Bela; Varga, Ilona; Boros, Imre; Jednakovits, Andrea; Nemeth, Ilona; Lonovics, Janos; Takacs, Tamas
CORPORATE SOURCE: First Department of Medicine, University of Szeged, Szeged, Hung.
SOURCE: Free Radical Biology & Medicine (2002), 32(12), 1283-1292
CODEN: FRBMEH; ISSN: 0891-5849
PUBLISHER: Elsevier Science Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Nontoxic heat shock protein (HSP) inducer compds. open up promising therapeutic possibilities by activating one of the natural and highly conserved defense mechanisms of the organism. In the present expts., we examined the effects of a HSP coinducer drug-candidate, BRX-220, on the cholecystokinin-octapeptide (CCK)-induced acute pancreatitis in rats. Male Wistar rats weighing 240 to 270 g were divided into two groups. In group B, 20 mg/kg BRX-220 was administered orally, followed by 75 μg/kg CCK s.c. three times, after 1, 3, and 5 h. This whole procedure was repeated for 5 d. The animals in group B received physiol. saline orally instead of BRX-220, but otherwise the protocol was the same as in group B. The rats were exsanguinated through the abdominal aorta 12 h after the last administration of CCK. We determined the serum amylase activity, the plasma trypsinogen activation peptide concentration, the pancreatic weight/body weight ratio, the DNA and total protein contents of the pancreas, the levels of pancreatic HSP60 and HSP72, the activities of pancreatic amylase, lipase, trypsinogen, and free radical scavenger enzymes (superoxide dismutase, catalase, and glutathione peroxidase), the degree of lipid peroxidn.,

protein oxidation, and the reduced glutathione level. Histopathol. investigation of the pancreas was also performed in all cases. Repeated CCK treatment resulted in the typical laboratory and morphol. changes of exptl. induced pancreatitis. The pancreatic levels of HSP60 and HSP72 were significantly increased in the animals treated with BRX-220. In group B, the pancreatic total protein content and the amylase and trypsinogen activities were significantly higher vs. group B. The plasma trypsinogen activation peptide concentration, and the pancreatic lipid peroxidn., protein oxidation, and the activity of Cu/Zn-superoxide dismutase were significantly decreased in group B vs. group B, whereas the glutathione peroxidase activity was increased. The morphol. damage in group B was significantly lower than that in group B. The HSP coinducer BRX-220, administered for 5 d, has a protective effect against CCK-induced acute pancreatitis.

REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2001:780856 CAPLUS

DOCUMENT NUMBER: 135:318423

TITLE: Preparation of N-[2-hydroxy-3-(1-piperidinyl)propoxy]pyridine-1-oxide-3-carboxamidine, N-[2-hydroxy-3-(1-piperidinyl)propoxy]pyridine-1-oxide-3-carboximidoyl chloride, and enantiomers thereof.

INVENTOR(S): Ueroegdi, Laszlo; Jeges Csakai, Zita; Gruber, Lajos; Oetvoes, Laszlo; Toth, Jozsef; Toemoeskoezi, Istvan; Szakacs Schmidt, Aniko; Reider, Ferencne; Schneidern Barlay, Maria

PATENT ASSIGNEE(S): Biorex Kutato es Fejleszto, Hung.

SOURCE: PCT Int. Appl., 29 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001079174	A1	20011025	WO 2001-HU46	20010417 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
HU 2000001583	A2	20021128	HU 2000-1583	20000418 <--
CA 2406266	A1	20011025	CA 2001-2406266	20010417 <--
EP 1274685	A1	20030115	EP 2001-928133	20010417 <--
EP 1274685	B1	20060712		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001010184	A	20030617	BR 2001-10184	20010417 <--
JP 2004501080	T	20040115	JP 2001-576775	20010417 <--
EE 200200591	A	20040415	EE 2002-591	20010417 <--
EE 5085	B1	20081015		
NZ 522017	A	20040625	NZ 2001-522017	20010417 <--
CN 1216868	C	20050831	CN 2001-810831	20010417

RU 2281282	C2	20060810	RU 2002-130710		20010417
AT 332894	T	20060815	AT 2001-928133		20010417
AU 2001254997	B2	20061123	AU 2001-254997		20010417
ES 2267758	T3	20070316	ES 2001-928133		20010417
IL 152337	A	20071031	IL 2001-152337		20010417
BG 107199	A	20030731	BG 2002-107199		20021016 <--
NO 2002005015	A	20021216	NO 2002-5015		20021018 <--
NO 323535	B1	20070604			
ZA 2002008460	A	20031020	ZA 2002-8460		20021018 <--
MX 2002010320	A	20040906	MX 2002-10320		20021018 <--
IN 2002KN01301	A	20050311	IN 2002-KN1301		20021018
KR 742482	B1	20070725	KR 2002-714047		20021018
US 20040006232	A1	20040108	US 2003-257755		20030128 <--
US 7126002	B2	20061024			
HK 1055741	A1	20060407	HK 2003-108135		20031110
PRIORITY APPLN. INFO.:			HU 2000-1583	A	20000418
			WO 2001-HU46	W	20010417

OTHER SOURCE(S): CASREACT 135:318423

AB Title compds. were prepared Thus, 2-hydroxy-4-azoniaspiro[3.5]nonane chloride was stirred in aqueous NaOH for 40 min. at 5-10°; EtOH and 3-pyridinamidoxime 1-oxide (preparation given) was added and the mixture was refluxed 2 h to give 62% N-[2-hydroxy-3-(1-piperidinyl)propoxy]pyridine-1-oxide-3-carboxamidine. The latter in aqueous HCl at -5° was treated with aqueous NaNO2 followed by stirring for 1.5 h to give 85% N-[2-hydroxy-3-(1-piperidinyl)propoxy]pyridine-1-oxide-3-carboximidoyl chloride.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 8 OF 14 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2000:608728 CAPLUS

DOCUMENT NUMBER: 133:207815

TITLE: Preparation of N-[2-hydroxy-3-(1-piperidinyl)propoxy]pyridine-1-oxide-3-carboximidoyl chloride and its use in the treatment of insulin resistance

INVENTOR(S): Kurthy, Maria; Biro, Katalin; Nagy, Karoly; Urogdi, Laszlo; Csakai, Zita; Szilbereky, Jeno; Mogyorosi, Tamas; Torok, Magdolna; Komaromi, Andras; Marvanyos, Ede; Barabas, Mihaly; Kardos, Mihalyne; Nagy, Zoltan; Koranyi, Laszlo; Nagy, Melinda

PATENT ASSIGNEE(S): Biorex Kutato Es Fejleszto Rt., Hung.

SOURCE: PCT Int. Appl., 36 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000050403	A1	20000831	WO 2000-HU15	20000224 <--
W: AU, BG, BR, CA, CZ, EE, HR, IL, IN, JP, KR, LT, LV, NO, PL, RO, RU, SI, SK, UA, US, YU, ZA				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2360451	A1	20000831	CA 2000-2360451	20000224 <--
BR 2000008969	A	20011127	BR 2000-8969	20000224 <--
EP 1163224	A1	20011219	EP 2000-909542	20000224 <--
EP 1163224	B1	20030416		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				

JP 2002537384	T	20021105	JP 2000-600986		20000224 <--
EE 200100447	A	20021216	EE 2001-447		20000224 <--
EE 4961	B1	20080215			
AT 237590	T	20030515	AT 2000-909542		20000224 <--
PT 1163224	T	20030731	PT 2000-909542		20000224 <--
ES 2193055	T3	20031101	ES 2000-909542		20000224 <--
AU 779096	B2	20050106	AU 2000-31824		20000224
RU 2250901	C2	20050427	RU 2001-126126		20000224
CZ 297386	B6	20061115	CZ 2001-3053		20000224
IL 144866	A	20070704	IL 2000-144866		20000224
PL 197692	B1	20080430	PL 2000-350915		20000224
IN 2001KN00785	A	20050311	IN 2001-KN785		20010731
ZA 2001006488	A	20020807	ZA 2001-6488		20010807 <--
HR 2001000584	A1	20020831	HR 2001-584		20010807 <--
BG 105837	A	20020329	BG 2001-105837		20010822 <--
BG 65178	B1	20070531			
NO 2001004103	A	20011022	NO 2001-4103		20010823 <--
NO 319793	B1	20050912			
US 6649628	B1	20031118	US 2001-913263		20011218 <--
PRIORITY APPLN. INFO.:			HU 1999-475	A	19990226
			WO 2000-HU15	W	20000224

AB N-[2-hydroxy-3-(1-piperidinyl)propoxy]pyridine-1-oxide-3-carboximidoyl chloride, its stereoisomers, and their acid addition salts, useful in treatment of pathol. insulin resistance, and for the treatment of pathol. conditions associated therewith, for the treatment of pathol. insulin resistance, were prepared

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 9 OF 14 EMBASE COPYRIGHT (c) 2009 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2005111731 EMBASE
TITLE: [Mice and humans [8]].
Mus og menn.
AUTHOR: Holmoy, Trygve
CORPORATE SOURCE: Ulleval Universitetssykehus.
SOURCE: Tidsskrift for den Norske Laegeforening, (26 Aug 2004) Vol. 124, No. 16, pp. 2156.
Refs: 2
ISSN: 0029-2001 CODEN: TNLAAH
COUNTRY: Norway
DOCUMENT TYPE: Journal; Letter
FILE SEGMENT: 037 Drug Literature Index
008 Neurology and Neurosurgery
LANGUAGE: Norwegian
ENTRY DATE: Entered STN: 24 Mar 2005
Last Updated on STN: 24 Mar 2005

L5 ANSWER 10 OF 14 EMBASE COPYRIGHT (c) 2009 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2004177118 EMBASE
TITLE: Putting the heat on ALS.
AUTHOR: Benn, Susanna C. (correspondence); Brown Jr., Robert H.
CORPORATE SOURCE: Day Lab. for Neuromuscular Research, Massachusetts General Hospital, Charlestown, MA 02129, United States. sbenn@partners.org; rhbrown@partners.org
SOURCE: Nature Medicine, (Apr 2004) Vol. 10, No. 4, pp. 345-347.
Refs: 15
ISSN: 1078-8956 CODEN: NAMEFI
COUNTRY: United Kingdom
DOCUMENT TYPE: Journal; (Short Survey)
FILE SEGMENT: 030 Clinical and Experimental Pharmacology

037 Drug Literature Index
005 General Pathology and Pathological Anatomy
008 Neurology and Neurosurgery
LANGUAGE: English
ENTRY DATE: Entered STN: 28 May 2004
Last Updated on STN: 28 May 2004

L5 ANSWER 11 OF 14 BIOSIS COPYRIGHT (c) 2009 The Thomson Corporation on STN
ACCESSION NUMBER: 2003:32824 BIOSIS
DOCUMENT NUMBER: PREV200300032824
TITLE: Effect of BRX-220 against peripheral neuropathy and insulin resistance in diabetic rat models.
AUTHOR(S): Kurthy, Maria [Reprint Author]; Mogyorosi, Tamas; Nagy, Karoly; Kukorelli, Tibor; Jednakovits, Andrea; Talosi, Laszlo; Biro, Katalin
CORPORATE SOURCE: Biorex Research and Development Company, P. O. Box 348, Veszprem-Szabadsagpuszta, H-8201, Hungary
Maria.Kurthy@biorex.hu
SOURCE: Klimes, Iwar [Editor, Reprint Author]; Sebokova, Elena [Editor]; Howard, Barbara V. [Editor]; Ravussin, Eric [Editor]. (2002) pp. 482-489. Lipids and insulin resistance: The role of fatty acid metabolism and fuel partitioning. print.
Publisher: New York Academy of Sciences, 2 East 63rd Street, New York, NY, 10021, USA. Series: Annals of the New York Academy of Sciences.
Meeting Info.: Fourth International Smolenice Insulin Symposium on Lipids and Insulin Resistance: The Role of Fatty Acid Metabolism and Fuel Partitioning. Smolenice, Slovakia. August 29-September 02, 2001.
ISSN: 0077-8923 (ISSN print). ISBN: 1-57331-368-8 (cloth), 1-57331-369-6 (paper).
DOCUMENT TYPE: Book; (Book Chapter)
Conference; (Meeting)
Conference; (Meeting Paper)
LANGUAGE: English
ENTRY DATE: Entered STN: 8 Jan 2003
Last Updated on STN: 11 Feb 2003

L5 ANSWER 12 OF 14 BIOSIS COPYRIGHT (c) 2009 The Thomson Corporation on STN
ACCESSION NUMBER: 2003:32816 BIOSIS
DOCUMENT NUMBER: PREV200300032816
TITLE: Comparison of the extrapancreatic action of BRX-220 and pioglitazone in the high-fat diet-induced insulin resistance.
AUTHOR(S): Sebokova, Elena; Kurthy, Maria; Mogyorosi, T.; Nagy, Karoly; Demcakova, Edita; Ukropec, Jozef; Koranyi, Laszlo; Klimes, Iwar [Reprint Author]
CORPORATE SOURCE: Diabetes and Nutrition Research Laboratory, Institute of Experimental Endocrinology, Slovak Academy of Sciences, Vlarska 3, SK-83306, Bratislava, Slovakia
ueeniwar@savba.sk
SOURCE: Klimes, Iwar [Editor, Reprint Author]; Sebokova, Elena [Editor]; Howard, Barbara V. [Editor]; Ravussin, Eric [Editor]. (2002) pp. 424-430. Lipids and insulin resistance: The role of fatty acid metabolism and fuel partitioning. print.
Publisher: New York Academy of Sciences, 2 East 63rd Street, New York, NY, 10021, USA. Series: Annals of the New York Academy of Sciences.

Meeting Info.: Fourth International Smolenice Insulin Symposium on Lipids and Insulin Resistance: The Role of Fatty Acid Metabolism and Fuel Partitioning. Smolenice, Slovakia. August 29-September 02, 2001.
ISSN: 0077-8923 (ISSN print). ISBN: 1-57331-368-8 (cloth), 1-57331-369-6 (paper).
DOCUMENT TYPE: Book; (Book Chapter)
Conference; (Meeting)
Conference; (Meeting Paper)
LANGUAGE: English
ENTRY DATE: Entered STN: 8 Jan 2003
Last Updated on STN: 11 Feb 2003

L5 ANSWER 13 OF 14 BIOSIS COPYRIGHT (c) 2009 The Thomson Corporation on STN
ACCESSION NUMBER: 2002:542301 BIOSIS
DOCUMENT NUMBER: PREV200200542301
TITLE: Non-toxic heat shock protein co-inducer BRX-220 protects against acute pancreatitis in rats.
AUTHOR(S): Rakonczay, Zoltan, Jr. [Reprint author]; Ivanyi, Bela; Varga, Ilona; Boros, Imre; Jednakovits, Andrea; Lonovics, Janos; Takacs, Tamas
CORPORATE SOURCE: Szeged, Hungary
SOURCE: Gastroenterology, (April, 2002) Vol. 122, No. 4 Suppl. 1, pp. A-283. print.
Meeting Info.: Digestive Disease Week and the 103rd Annual Meeting of the American Gastroenterological Association. San Francisco, CA, USA. May 19-22, 2002.
CODEN: GASTAB. ISSN: 0016-5085.
DOCUMENT TYPE: Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LANGUAGE: English
ENTRY DATE: Entered STN: 23 Oct 2002
Last Updated on STN: 23 Oct 2002

L5 ANSWER 14 OF 14 BIOSIS COPYRIGHT (c) 2009 The Thomson Corporation on STN
ACCESSION NUMBER: 2002:4500 BIOSIS
DOCUMENT NUMBER: PREV200200004500
TITLE: Prevention of axotomy-induced motoneuron death by treatment with BRX-220, a co-inducer of heat shock proteins.
AUTHOR(S): Kalmar, B. [Reprint author]; Burnstock, G.; Vrbova, G.; Hargitai, J.; Urbanics, R.; Greensmith, L. [Reprint author]
CORPORATE SOURCE: Inst Neurology, University College London, London, UK
SOURCE: Society for Neuroscience Abstracts, (2001) Vol. 27, No. 2, pp. 2477. print.
Meeting Info.: 31st Annual Meeting of the Society for Neuroscience. San Diego, California, USA. November 10-15, 2001.
ISSN: 0190-5295.
DOCUMENT TYPE: Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LANGUAGE: English
ENTRY DATE: Entered STN: 28 Dec 2001
Last Updated on STN: 25 Feb 2002
AB Heat shock proteins (hsps) are induced in a variety of cells in response to stress. We examined the effect of BRX-220, a co-inducer of hsps, on axotomised motoneurons. Following sciatic nerve crush at birth, rat pups were treated daily with BRX-220 (10 mg/kg, i.p.). The effect on motoneuron survival was assessed by counting the number of Nissl-stained motoneurons. The number of

functional motor units was assessed by in vivo isometric tension recordings. Hsp expression was examined both in vivo and in vitro by immunostaining, western blot analysis and Elisa. BRX-220 treatment significantly improved the survival of injured motoneurons. Thus, 39% (+-2.8 SEM., n=7) of motoneurons survived 14 days after injury in the treated group compared to only 21% (+-1.7 SEM., n=7) in untreated group. This improvement in motoneuron survival was also observed 10 weeks after injury and was reflected in an increase in the number of functional motor units in the hindlimb muscles. The expression of hsp 70 and 90 was found to increase following BRX-220 treatment both in vivo in axotomised spinal cords and in vitro in heat shocked H9c2, 3T3 and Wehi-164 cells, where 10-5-10-6 M BRX-220 increased hsp70 levels by approximately 30 to 50%, as measured by ELISA and western blot analysis. Therefore, BRX-220 protects motoneurons from axotomy-induced cell death. This effect may be due to its ability to act as a co-inducer of hsps. Thus, it may be possible to rescue injured neurons by enhancing their own cellular defence mechanisms.